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1. INTRODUCTION 
Dengue is a re-emerging, mosquito-borne viral disease in the world. 
Dengue fever (DF) and its severe forms like dengue haemorrhagic fever (DHF) 
and dengue shock syndrome (DSS) have become major international public 
health concern.1 Children are at higher risk and the mortality rate during 
secondary infection is nearly fifteen times higher than the risk in adults.2 Since 
there is no immunoprophylaxis or specific antiviral treatment available, timely 
and rapid diagnosis plays an important role in patient management and 
application of control measures to prevent high morbidity and mortality. 
1.1. History 
Dengue fever was first referred as “water poison” associated with flying 
insects in a Chinese medical encyclopedia in 992 from the Jin Dynasty (265-420 
AD). The word “dengue” is derived from the Swahili word Ka-dinga pepo, 
meaning “cramp-like seizure”. The name Break bone fever was first applied by 
Benjamin Rush in 1789. The clinically recognized dengue epidemics occurred 
almost simultaneously in Asia, Africa, and North America in 17th century and 
were infrequent until 1940. The name Dengue fever came in to use only after 
1828. The Aedes mosquito was confirmed as the transmitting agent in 1906, and 
the causative agent was identified as virus in 1907. The first report of DHF was 
from Philippines in 1953.3   
  
2 
 
1.2. Global scenario         
Over the last five decades the incidence has raised 30 fold and the disease 
has expanded itself to new geographical locations and also from urban to rural 
areas. Now Dengue is endemic in more than 100 countries in the regions of 
Africa, the Americas, the Eastern Mediterranean, South-East Asia and the 
Western Pacific. The South-East Asia and Western Pacific regions are the most 
seriously affected.1        
About 2.5 billion people, the two fifths of the world’s population in 
tropical and subtropical countries are at risk. An estimated 50-100 million 
dengue infections occur worldwide and around 5,00,000 affected people require 
hospitalization every year. The mortality rate of DF is less than one percent, for 
DHF this is approximately 5%, when patient   develops DSS it is as high as 
40%. A large proportion (approximately 90%) of them are children aged less 
than five years, and about  2.5% of those affected die of complications.1      
1.3. Indian scenario 
 DF/DHF is endemic in most countries of the South East Asian region 
and detection of all four serotypes has now rendered these countries 
hyperendemic. As per WHO 2011 report, India is classified under category A 
for the following reasons, hyperendemicity with all four serotypes in urban 
areas and spreading to rural areas, the leading cause of  hospitalization and 
death among children and a major public health concern.  
 The first proved epidemic of DF in India occurred in Eastern Coast of India in 
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1963-19644.  
One of the largest outbreaks in India occurred in Delhi in 1996 which was 
mainly due to dengue-2 virus. Thereafter, in 2003, another outbreak occurred in 
Delhi in which dengue-3 was the predominant serotype.5         
1.4. Dengue in Tamil Nadu 
Dengue has been rampant in parts of Tamil Nadu in the past two decades. 
The prevalence of dengue vector and silent circulation of dengue viruses have 
been detected in rural and urban Tamil Nadu, which is ever increasing.6 
1.5. Morphology of dengue virus3  
The dengue virus belongs to the family Flaviviridae and genus 
Flavivirus. They are small (50nm) enveloped viruses and the  nucleocapsid 
exhibits cubic symmetry. Their single stranded RNA genome is 11,644 
nucleotides in length and contains three structural protein genes encoding the 
nucleocapsid or core protein (C), a membrane-associated protein (M), an 
envelope protein (E) and seven non-structural protein (NS) genes NS1, NS2a, 
NS2b, NS3, NS4a, NS4b, NS5.(Figure 1)              
There are four distinct closely related serotypes of Dengue virus          
(DENV-1, DENV-2, DENV-3, and DENV-4). Distinct genotypes have been 
identified within each serotype. Currently, three sub-types exist for DENV-1, 
six for DENV-2, four for DENV-3 and four for DENV-4.1,3   
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1.6. Structural Proteins 
1.6.1. C Protein     
Nucleocapsid or core (C) protein is the first viral polypeptide synthesized 
during translation. It protects the viral nucleic acid from inactivation and   
introduces the viral genome into host cells. 
1.6.2. M protein  
The membrane associated protein M is derived from the precursor protein 
prM during virus maturation. The role of M protein in the mature virion is not 
known. 
1.6.3. E glycoprotein  
It is a major virion envelope glycoprotein. E-protein acts as the target and 
as the modulator of host immune response. Most of the molecular markers for 
pathogenicity have been localized in the E gene. 
1.7. The Nonstructural Proteins            
         NS1 contains 12 completely conserved cysteine residues. The 6 
conserved disulfide bridges are likely to be critical determinants of antigenicity 
and function. In infected cells in vitro, NS1 is detected intracellularly, on the 
surface, and secreted in copious amounts into the medium.3 
NS1 elicits humoral and cellular immune response. Passive transfer of 
NS1 antibodies can confer protection against DENV infection in experimental 
animals and NS1 has been evaluated as a candidate vaccine that can induce a 
protective immune response in experimental animals against homologous 
5 
 
challenge with DENV. NS1 plays a role in pathogenicity, due to epitopes that 
mimic those of endothelial cell surface molecules. Antibodies to such shared 
epitopes induce endothelial cell damage and elicit inflammatory cytokines that 
may play a role in the hemorrhage associated with dengue infection.        
The non structural proteins are involved in the RNA replication and virus 
assembly. NS2b, NS4a and NS4b proteins are enzyme cofactors. NS3 and NS5 
proteins are viral proteases.3 
1.8. The vector  
Aedes (Stegomyia) mosquito species such as. Ae. aegypti, Ae. albopictus, 
Ae. polynesiensis  and  some members of  Ae. scutellaris act as vector. Among 
these Aedes aegypti is the commonest.3 The viruses are maintained in a 
mosquito-human-mosquito cycle, with periodic epidemics occurring at 3 to 5 
year intervals.  
The larval stages are found mostly in artificial containers with water 
around human dwellings where they mature into adults. The people, rather than 
mosquitoes, transmit the virus within and between communities.1                         
The mosquitoes become infected when they imbibe blood from a viremic 
host. In the mosquito the virus infects epithelial cells lining the midgut wall and 
subsequently spreads to other organs after 8 to 12 days, transmitting the virus to 
other humans during subsequent feeding. 
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  The Ae.aegypti female feeds on several persons to fulfill a single blood 
meal and transmitting the virus to multiple persons within a short period of 
time, making it an efficient epidemic vector.7  
 1.9. Factors influencing transmission 
Uncontrolled urbanization, expanding urban population, poverty, 
ineffective public health infrastructure, faster modes of transportation, 
globalization of trade and increased international travel have all been implicated 
as factors leading to the spread of dengue around the world. Rapid urbanization 
is probably the single most important contributing factor resulting in poor 
sanitation and lack of potable water supply. So the residents have resorted to 
using containers to store water which often ends up as breeding sites for the Ae. 
aegypti vector.7  
1.10. Host immune response  
After an incubation period of 4 -10 days, infection in humans produce a 
wide spectrum of illness, most infections being asymptomatic.  
During the acute phase of illness viremia lasts for 5 days and immune 
response clears the virus via neutralizing antibodies or by activation of T 
lymphocytes.                                                                                                                                                                             
Infection with any one serotype provides lifelong immunity against 
homologous reinfection. The subsequent infection by different serotype 
increases the risk of development of severe manifestations.1 
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Severe dengue can also occur in infants born to Dengue-immune 
mothers.8        
 1.11. Pathogenesis and pathophysiology  
The immune system plays a role in the pathogenesis of DHF/DSS and 
secondary dengue infections. Basically, at least two theories have been 
presented to explain the severity of DHF. According to the first theory of 
Antibody dependent enhancement (ADE),(Fig -2) previous antibodies of a 
specific serotype of dengue virus bind to different dengue virus serotype 
producing non neutralized antibody–virus complexes. These complexes bind to 
macrophages which lead to activation of T cells from previous presentation to 
Major Histocompatibility Complex molecules (MHC) and cytokines like 
interferon-γ, Tumor Necrosis Factor, IL1, IL6, IL8 are produced. Additionally, 
Vascular Endothelial Growth Factor (VEGF) is produced by monocytes and 
endothelial cells produces changes in vascular permeability due to functional 
alteration in vascular integrity resulting in selective leakage of plasma in the 
pleural and peritoneal cavities, contracted intravascular volume and shock in 
severe cases.9 
According to the second theory, specific genotypes of dengue virus which 
are more virulent could be the cause of more severe symptoms of dengue. 
Epidemiological studies show the relationship between severity of 
epidemics and previous serological conditions of the population affected. 
Sequence of infection with DENV-1 virus followed by DENV-2 has been 
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demonstrated to correlate with high rates of DHF.10  
Severity of dengue correlates with high viral load, secondary dengue 
infection, DENV-2 virus type, virulence of the strain and the genetic difference 
in the hosts.11  
1.12. Clinical presentation   
Dengue infection may be asymptomatic or may cause dengue fever (DF) 
or dengue haemorrhagic fever (DHF) including dengue shock syndrome (DSS).1 
According to WHO, a clinical case of Dengue Fever is an acute febrile 
illness with frontal headache, retroocular pain, muscle pain, joint pain and rash; 
even though other signs and symptoms could also be present (such as 
lymphadenopathy, petechiae, nausea, hepatomegaly and different types of 
hemorrhagic manifestations).  
A probable case of DF is defined as cases with fever and two or more of 
the following: headache, retro-orbital pain, myalgias, arthralgias, rash, 
hemorrhagic manifestation and supportive serology (HAI,IgG,IgM tests) or 
occurrence at the same location and time as other confirmed cases of dengue.7 
A confirmed case of DF is defined as cases with isolation of dengue virus 
from serum or autopsy sample; or demonstration of fourfold change in 
reciprocal IgG or IgM antibody titers in paired serum samples; or demonstration 
of dengue virus antigen in autopsy tissue, serum or cerebro-spinal fluid samples 
by immunohistochemistry, immunofluorescence or ELISA; or detection of virus 
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genome sequence in autopsy tissue, serum or cerebro-spinal fluid samples by 
RT-PCR. 
Dengue Haemorrhagic Fever 
Dengue Hemorrhagic Fever case has to have all the four following 
criteria: Fever, hemorrhagic tendencies (including Tourniquet test), low platelet 
count (1x105 per mm3 or less) and plasma leakage ( hematocrit  >20%, signs of 
plasma leakage: pleural effusion, ascites and hypoproteinemia).1         
DHF is classified into four grades of illness based on severity (WHO 
1997)   
Grade I is mild; Fever, haemorrhagic manifestations and evidence of 
plasma leakage. 
Grade II is more severe: Grade I plus spontaneous bleeding.                                        
Grade III is Grade II plus signs of circulatory failure.  
Grade IV is Grade III plus profound shock.       
  The Grade III and IV is Dengue shock syndrome. 
        With the recent revision of dengue classification scheme by World Health 
Organization, patients are classified as having either dengue or severe dengue. 
Patients who recover without major complications are classified as having 
dengue. Those who have  plasma leakage  resulting in shock, accumulation of 
serosal fluid  causing  respiratory distress, or both; severe bleeding; and severe 
organ impairment are designated as  severe dengue cases. 
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1.13. Complications      
Complications in Dengue infections occur usually due to prolonged shock 
leading to metabolic and electrolyte disturbance with various manifestations 
like febrile seizure in young children, encephalopathy, severe bleeding as a 
result of disseminated intra vascular coagulation and multi organ failure such as 
hepatic and renal dysfunction. The treatment related complications due to fluid 
volume overload can occur. The other complications are aseptic meningitis, 
encephalitis, myocarditis, haemolytic uremic syndrome, pancreatitis, transverse 
myelitis, macular haemorrhage and optic neuritis.3 
1.14. Differential diagnosis  
It includes influenza, measles, rubella, chikungunya, enteric fever, 
malaria, viral hepatitis, leptospirosis, rickettsial diseases and bacterial sepsis. 
The infections that may clinically mimic dengue are other viral hemorrhagic 
fevers, and arboviral infections that may be accompanied by rash and resemble 
Dengue fever include, O’nyong nyong, Sindbis, Mayaro, Ross River and West 
Nile viruses.3 
1.15. Laboratory diagnosis of dengue infection   
Rapid and accurate dengue diagnosis is of paramount importance for 
epidemiological surveillance, clinical management and vaccine trials. 
Epidemiological surveillance requires early determination of dengue virus 
infection during the outbreak for urgent public health action towards control and 
detection of circulating serotypes/genotypes during the inter-epidemic periods 
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for use in forecasting possible outbreaks. Clinical management requires early 
diagnosis of cases, confirmation of clinical diagnosis and for differential 
diagnosis from other flaviviruses /infection agents.   
The following laboratory tests are available for diagnosis of dengue 
infections. 
1. Virus isolation / serotypic/genotypic characterization 
2. Viral nucleic acid detection 
3. Viral antigen detection 
4. Immunological response based tests- IgM and IgG antibody assays. 
       During the early stages of the disease (up to six days of onset of illness), 
virus isolation, molecular techniques or antigen detection is used, after which 
immunological tests are used for diagnosis. 
1.15.1. Virus isolation  
Viral isolation is the most sensitive way to detect dengue virus. The 
techniques used are: 
1. Mosquitoes (pool of 15 to 20) are inoculated either with serum, or plasma, or 
pleural fluid or other sterile body fluid. After incubation virus infection is 
confirmed by immunofluorescence. This is the most sensitive isolation 
technique.  
2. Inoculation of mammalian or insect cell cultures (usually C6/36) is other 
common method used for viral isolation. The presence of the viruses is 
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confirmed by cytopathic effect or plaque formation assay. RNA detection 
and immunofluorescence also can confirm the infection. 
3. Intracranial inoculation of sucking mice is used to isolate dengue virus; 
either encephalitis signs or antigen in brain tissue are evidence of infection.  
The higher limitation of the viral isolation is that it is time consuming, 
and also there is high cost associated with use of the cell culture method.  
1.15.2. Viral nucleic acid detection    
 Molecular diagnosis is more sensitive and rapid than virus isolation. In 
recent years, a number of RT-PCR assays like RT-PCR, Nested PCR, one step 
multiplex PCR, Real time RT-PCR and Isothermal amplification method have 
been reported. Recently, Loop Mediated Amplification (LAMP) PCR method 
has been developed, which promises an easy-to-do and less expensive 
instrumentation alternative for RT-PCR and real-time PCR assays. However, 
molecular diagnoses are costly, require specialized laboratory equipments and 
experienced technicians.  
1.15.3. Viral Antigen detection 
 The NS1 gene product, needed for replication and viability is formed by 
all flaviviruses. The protein is produced by infected mammalian cells and the 
antigen appears as early as the 1st day of fever declining to untraceable levels by 
5–6 days.  
 NS1 antigen is present in high concentrations for up to six days after the 
onset of the illness in both primary and secondary dengue infections. However, 
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the kits do not differentiate between the serotypes. Besides providing an early 
diagnostic marker for clinical management, it may also facilitate the 
improvement of epidemiological surveys of dengue infection. 
 The newer diagnostic assays for E, NS3 and NS5 antigen detection allows 
the diagnosis of dengue with higher sensitivity during acute phase of infection.11         
 The Immunoperoxidase and avidin-biotin enzyme assays allow detection 
of dengue virus antigen in acetone-fixed leucocytes and in snap-frozen or 
formalin-fixed tissues collected at autopsy. 
1.15.4. Viral Antibody detection  
The use of immunological test is based in the immune response after 
being exposed to the Dengue virus. Antibody response to infection leads to the 
appearance of different types of immunoglobulins. Detection of 
immunoglobulin M (IgM) and immunoglobulin G (IgG), each one or in 
combination, are used in the diagnosis of dengue infection. A definitive 
diagnosis requires a pair of samples, which need to be collected during the acute 
and convalescence phase.  
During primary infection, the IgM antibodies are detectable by days 3 to 
5 after the onset of illness, rise quickly by about two weeks and decline to 
undetectable levels after 2–3 months. IgG antibodies are found at low level by 
the end of the 1st week, increase subsequently and remain for many years.7 
During secondary dengue infection, antibody titres rise rapidly. IgG 
antibodies are demonstrable at high levels, even in the initial stage, and persist 
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lifelong. IgM antibody levels are significantly lower in secondary infection 
cases. Hence, a ratio of IgM/IgG is commonly used to differentiate between 
primary and secondary dengue infections. 
Several methods like Enzyme linked immunosorbent assay (ELISA), 
Haemagglutination inhibition test (HAI), complement fixation test and 
neutralization test are used for the serological diagnosis of dengue. 
Among those, IgM/IgG capture ELISA is the most commonly used 
serological technique for routine diagnosis due to its high sensitivity, 
specificity, simplicity, and feasibility for automation.HAI test has recently 
become less popular due to the inherent disadvantages of the test.  
A number of commercial rapid format serological tests have become 
available in the past few years, some of these producing results within 15 
minutes. But the accuracy of most of these tests is uncertain as they have not 
been validated yet. Rapid tests can yield false positive results due to cross-
reaction with other flaviviruses, malaria parasite, leptospires and immune 
disorders such as rheumatoid and lupus. But in an outbreak situation, if more 
than 50% of specimens test positive when rapid tests are used, dengue virus is 
then highly suggestive of being the cause of febrile outbreak.1 
1.16. Interpretation of dengue diagnostic test1 
Highly suggestive of dengue infection 
One of the following: 
1) IgM positive in a single serum sample. 
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2) IgG positive in a single serum sample with a HAI titre of 1280 or greater. 
Confirmed dengue infection 
One of the following: 
1) RT-PCR positive. 
2) Virus culture positive. 
3) IgM seroconversion in paired sera. 
4) IgG seroconversion in paired sera or fourfold IgG titre increase in paired 
sera. 
1.17. Treatment and prevention       
Proper and early treatment can relieve the symptoms and prevent 
complications and death. In the early febrile phase, since it is not possible to 
distinguish Dengue fever from Dengue Haemorrhagic Fever clinically, the 
treatment is symptomatic and supportive care only. There is no role for 
antibiotics and steroids. Timely intravenous fluid therapy can prevent shock 
and/ or lessen its severity. In case of severe bleeding or reduction in haematocrit 
fresh blood transfusion must be required.1 
There are three approaches to prevent dengue disease,  
1. To detect the cases and the virus in early periods of viral activity by 
epidemiological surveillance either to reduce or prevent the impact of the 
epidemic.  
2. To halt the infectious chain reducing or eliminating the vector mosquito 
before transmission, during and after rainy season. 
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3. To block the virus action inside the human hosts with use of vaccine to 
induce specific immunization. With a mixture of environmental 
management, health education and community participation the disease 
can be eradicated.1  
Multicentric phase 2, 3 trials are in progress to determine the efficacy of 
ChimeriVax (Sanofi Pasteur), a tetravalent formulation of attenuated yellow 
fever 17D vaccine strains expressing the dengue virus prM and E proteins. 
Long-term follow-up will be essential to assess whether waning vaccine-elicited 
immunity leads to severe outcomes on subsequent natural infection. Live 
attenuated dengue viruse vaccines and recombinant subunit vaccines are in the 
row.12   
Since differentiation of dengue from other febrile illnesses in acute phase 
is clinically difficult, definitive and early diagnosis relies on laboratory tests 
which is important in the therapeutic intervention to decrease morbidity and 
mortality.  
Due to the rising importance of early and prompt dengue infection 
detection, this study was aimed to analyze the importance of NS1 antigen 
detection in early diagnosis of dengue and its correlation in primary and 
secondary infection. 
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2. AIM AND OBJECTIVES 
1. To study the prevalence of dengue in paediatric age group. 
2. To study the importance of NS1 antigen in the diagnosis of dengue 
infection. 
3. To demonstrate the importance of paired serum samples in the 
interpretation of dengue infections.                                                     
 
 
 
 
 
 
 
 
 
 
 
18 
 
3. REVIEW OF LITERATURE 
Dengue, a serious mosquito borne infection in humans occurs during 
rainy season and affects over hundred million people every year with high death 
rate in children. A primary dengue infection provides lifelong immunity against 
the infecting serotype and a brief protection against infection by other DENV 
serotypes.2 But this increases the probability of an individual developing DHF 
when infected by a second heterologus DENV serotype due to antibody 
dependant enhancement. Till date there is no effective antiviral drug or vaccine 
for this disease. Prevention, early diagnosis and supportive care are the 
mainstay of treatment in dengue infection. 
Dengue virus was first isolated by Ren Kimura and Susumu Hotta in 
Japan in 1943. A few months later Albert Bruce Sabin and Walter Schlesinger 
isolated dengue virus from Hawaii.13 Of the four serotypes DENV 2 and DENV 
3 are associated with severe disease.  
3.1. Global prevalence of dengue 
Historically, there are at least three different sources providing report 
about the first dengue case; chronologically, a report from China provided the 
first description of a disease compatible with dengue in 610 A.C. The second 
report that probably registered the source of dengue outbreak was in West 
French Indies in 1635. Finally, and usually the most cited dengue report was 
from Philadelphia in the summer of 1779.7 
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The first epidemic of DHF occurred in Manila, Philippines, in 1953 to 
1954 and within 20 years, the disease in epidemic form had spread throughout 
Southeast Asia. By the mid-1970s, DHF had become a leading cause of 
morbidity, since then the disease has increased more than four fold. 
During the 1980s and 1990s epidemic Dengue transmission intensified, 
and there was  a global resurgence of Dengue fever, with expanding geographic 
distribution of both the  vectors and the viruses  and the emergence of DHF in 
many  countries. In 1998 alone, more than 1.2 million cases were reported to the 
World Health Organization, with south-east Asia, the western Pacific and more 
recently the America being the most affected regions. 
In the South East Region of Asia from 2000 to 2005, the highest cases of 
dengue were in Maldives, Thailand, Sri Lanka and Indonesia.1  
3.2. Dengue seroprevalence 
In Indonesia dengue serotype antibody prevalence was estimated twice 
during a one year interval. In the beginning a study conducted among 1,837 
children aged 4 to 9 years in 1995 showed 56.1 % of the children were positive 
to dengue antibodies.14   
In Vietnam, Thai et al15 (2005) reported sero-prevalence of 65.7 % in 
schoolchildren aged 7 to 14 years. 
A prospective study made by Balsameda et al16 (2006) in Nicaragua 
among children 4 to 16 year old and reported that the overall prevalence was 
91%, increasing from 75% at age 4 to 100% at age sixteen.  
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In Maracay of Venezuela, a prospective study performed on  
schoolchildren aged 5 to 13 years showed the  prevalence of anti dengue 
antibody to be 51 % ; amongst which 30.1 % tested with immune response to 
one serotype, and 20.9% to two or more serotypes. The highest antibody 
prevalence was for DENV-2 (14.2%) followed by DENV-1 (13.4%). Among 
the previously seronegative children, 25.6% seroconverted and 26% of the 
children seroconverted with secondary infection.17  
3.3. The Indian Scenario 
Dengue haemorrhagic fever was first reported in 1963 from Calcutta. The 
next major epidemic of DHF occurred in New Delhi in 1996 when 10,252 cases 
and 423 deaths were reported with the proportion of DHF to DF being very 
high.  
Out of 35 States / Union-territories in the country 29 have reported 
dengue cases mainly due to DENV 2 and deaths due to DENV 3.  
During the post epidemic period of 1997, DENV-1 activity was seen in 
New Delhi.  The cases and deaths were low till 2002 but again it raised in 2003, 
when another outbreak occurred where all four serotypes were co-circulating 
with a predominance of DENV 3. 5  
In 2004, DENV 1 was found to be circulating and in 2005 DENV 3 
emerged as the predominant serotype. 
In 2005, the cases and deaths showed threefold increase compared to 
2004.  
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PM Ukey et al (2010)18 in his study observed that the sero prevalence in 
Central India was 31.3% from the period of 2005 to 2006. In Andhra Pradesh in 
South India, Neeraja et al19 tested 260 dengue suspected cases during 2004 
outbreak and reported sero positivity in (81%) patients. 
3.4. Dengue in Tamil Nadu  
      The first evidence of Dengue fever in the state was documented from 
Vellore District, Tamil Nadu in 1956.20   In South India particularly in 
Tamilnadu DF and DHF have been well documented.21 
Of the 30 districts in Tamilnadu, dengue cases have been reported from 
29 districts between 1998 and 2005 which include DF / DHF outbreaks in 
Chennai 2001, Nagerkoil 2001 and Thiruchirapalli 2003 and Dengue fever 
outbreaks in Krishnagari and Dharmapuri Districts in 2001. Total of 128 cases 
and 5 deaths were reported in 1998 which increased to 1600 cases and 12 deaths 
in 2003 and 1150 cases and 8 deaths in 2005.Dengue cases have not been 
reported from Nilgris District probably due to high altitude.22 
In Chennai, uncomplicated Dengue fever (DF) was prevalent among 
children and adults and DHF has been largely restricted to infants and children. 
Since 2005 Chennai is witnessing DHF among young as well as elderly adults.23 
During July 2007, Dengue fever suspected cases were reported from two 
rural areas namely O.Alankulam and P.Alankulam near Madurai, TamilNadu.24 
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3.5. Dengue season 
Due to the rise of the larval population in the rainy season epidemics of 
dengue tend to occur during that time. The rainy season provides the required 
temperature and humidity for the propagation of virus in mosquitoes. The 
temperature of the environment also influences the time taken for the virus to 
multiply in mosquito, especially rainy season being favourable for the virus to 
cause early acute viraemia. Gupta E et al25 observed that the seasonal trend of 
dengue virus infection is reflected by the peak of positive cases observed during 
post monsoon season. 
Barbazan et al26 (2002) in Thailand observed in their study that dengue 
was more prevalent during and after rainy season, when vector breeding is 
maximal. 
R.K.Ratho et al27 (2006) noted that, between 1996 to 1999 large cases of 
dengue occurred from September to November. 
 3.6. Dengue in rural area 
In the 1960s and 1970s dengue was mainly an urban disease but with the 
usage of piped water supply by the rural communities, it made it entry into rural 
areas of South India.28 
S.C.Tewari et al6 (2004) concluded from their entomological study that 
villages in South India are known for the hyper-endemicity of dengue where all 
the four serotypes are circulating and prone for outbreak. 
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Arunachalam et al29 (2004) from their study reported dengue cases for the 
first time in a rural area of Kurnool District, Andhra Pradesh.  
3.7. Dengue in children  
WHO (1997) estimation of dengue data suggest that annually hundred 
million cases of dengue fever and fifty thousand cases of dengue haemorrhagic 
fever (DHF)  are occurring worldwide with a fatality rate of 0.5%–3.5% in 
Asian countries. Of those with DHF, ninety percentages are children less than 
15 years of age.    
Maria Guzman et al2 in 2002 analysed the sero epidemiological data from 
1981 epidemic of Cuba and reported that children, aged 3 and 4 years, with 
secondary DEN-2 infections were found to have a high death rate. The death 
rate for children aged 3-14 years was 14.5-fold higher than in young adults aged 
15-39 years.        
In Thailand, data from 1974 to 199330 showed that dengue was common 
in children aged less than 15 years of age and the incidence rates among 
children hospitalized with dengue have been consistently highest in the 5–9 year 
age group.       
 Rosario et al8 in his study observed that the infants in endemic area are 
more prone to develop dengue. In 2007, the incidence of asymptomatic dengue 
infections during infancy was 103 per 1,000 person-years which were six times 
higher than symptomatic cases. DHF was known to occur in 0.5 per 1,000 
persons who were in the age of 3–8 months, and it was not present by age 9 
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months because younger infants are more likely to have protective levels of 
maternally derived anti-DENV antibodies. 
3.8. Risk factors  
Risk factors include the infecting type of the virus, virulence of the virus, 
gender, immunological status and hereditary background of the host.31  
Death rate and hospitalization rates because of DHF/DSS are maximum 
following a secondary DENV 2 infection. 
Neeraja et al19 in 2012 showed the male female ratio to be 2:1.Ole 
Wichman et al32(0.96:1) and  Kabra et al33  reported  that  DHF to be more 
severe among females. 
A study among 165 patients by Narayanan et al34 showed that the 
occurrence of male, female dengue cases were 52.4%, 47.6% respectively. 
Gomber et al35 found it to be 56%  and  44%,  and Aggarwal et al36 as  60%  & 
40% males and  females respectively.  
Malnutrition appears to   be an uncommon risk factor for DHF. It is 
common among patients suffering from diabetes mellitus and bronchial 
asthma.37 
3.9. Clinical profile 
Ratgeri et al38 (2005) observed  clinical features and lab findings such as  
fever (100%), vomiting (82%), pain abdomen (61%), headache (22%), Gastro 
intestinal  bleeding ( 22%), petechiae (18%), WBC count less than 5000/cumm 
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(26%), platelet count below 1 lakh/µl (82%), pleural effusion (70%) and ascites 
as USG finding (54% ) of cases in his study. 
Aggarwal et al36 (1997) observed the following findings. Among 134 
cases, fever (93%), vomiting (68%), abdominal pain (49%), haematemesis 
(39%), epistaxis (36%) and skin bleeds in 33% of cases. WBC counts below 
4000/cumm were observed in 15% of cases, platelet below 50,000/µl in 69% 
and haematocrit more than 40% in 18% of cases. 
Narayanan et al34 (2002) among 59 patients observed, fever 
98.3%,vomiting 83%,headache 28.8%, retro orbital pain in 11.9%, abdominal 
pain 23%,bleeding  66.1% ,rash 8.5%, fall in  haematocrit in 24.1% and platelet 
count below 1 lakh in 39% of cases.  
3.10. Mortality 
DENV infections cause illness in tens of millions each year throughout 
the tropics and subtropics, severe morbidity in approximately 2 million 
persons/year, and approximately 20,000 deaths/year. The mortality of dengue 
from various studies  reported  were 12-13% (Kabra et al,33 6% ( Aggarwal et 
al),36  4.8% (Gomber et al),35  3.3% (Narayanan et al),34  5.2 % (Neeraja et al)19 
and  nil mortality (Kabilan et al 2001).39 
3.11. Detection methods 
NS1 antigen  
Dengue NS1 protein is found to be circulating in early period of illness 
and does not have cross reaction with Japanese encephalitis or yellow fever. 
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NS1 antigen detection is an effective test for the diagnosis of dengue during the 
early stage. NS1 antigen is noticeable in blood from the first day after the onset 
of fever up to Day 9; once the clinical phase of the disease is over it is still 
detectable even when viral RNA is negative by RT-PCR and in the presence of 
IgM antibodies.  
Alcon et al (2002)40 analysed 127 panel of sera from 61 patients and 
determined the NS1 antigen level each day. They observed that it was 80% 
positive on day one,60% positive on day two,100% positive on day four and 
five, 80% on day six and  it was hardly detected between days seven  & nine 
and never detected after day ten.   
Xu et al41 (2006) analysed specimens from clinically suspected dengue 
patients and observed that NS1 antigen could be detected till the 18th day after 
the start of illness with increased levels on days six to ten. Both NS1 and IgM 
were present in the acute phase, but during first three days, NS1 antigen 
detection was more sensitive. 
Dussart et al (2006)42 analysed 239 acute serum samples for NS1antigen 
and compared with RT-PCR, which showed low sensitivity for NS1 from day 5 
and suggested the possibility of immune complexes production from day 5. 
They concluded that NS1 antigen detection could be used for first line testing 
from day 0 – 4 of onset of fever for primary dengue fever and suggested the 
study of paired sera for analyzing the effectiveness of NS1 antigen in severe 
dengue disease.  
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Mini P.singh et al(2010)43 has evaluated and compared NS1 with IgM for 
diagnosis of acute dengue virus infection in 87 patients and said that  NS1 
antigen had a sensitivity of 71% to 100% in patients who had fever for 3 days. 
They suggested that NS1 antigen should be considered as the test of choice for 
patients presenting with fever upto 3 days and it was not useful beyond day 4 of 
fever. 
Kovi  Bessof et al (2008)44 conducted a study among 208 acute serum 
samples and concluded that NS1 detection can improve dengue virus diagnosis. 
A.Shrivastava et al (2011)45  in their study evaluated NS1 antigen 
detection among 91 acute serum samples and compared it with RT-PCR. Their 
results showed that 26% were positive for NS1 antigen and only 12% were 
positive by RT-PCR. They concluded that plasma viremia levels had correlation 
with the detection of NS1 and reported that patients who tested positive for NS1 
antigen had high viremia levels and vice versa. So acute dengue cases with low 
viremia can be NS1 negative and the sensitivity of NS1 decreases with 
increasing time as the viral load comes down in these patients. NS1 has a high 
Positive predictive value in the diagnosis of dengue, but negative NS1 does not 
rule out dengue fever. 
Kwoon-Yong Pok (2010)46 in his study, compared the detection of  NS1 
antigen with RT-PCR in dengue diagnosis and stated that it is  an  effective  
alternative choice  to RT-PCR.          
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Duong et al (2011)47 conducted a study among 260 confirmed dengue 
patients and reported that the sensitivity of NS1 test increased when combined 
with MAC-ELISA.  
Chua et al (2011)48 conducted a prospective study to evaluate the 
sensitivity of  Dengue NS1 antigen  detection in 558 acute phase serum samples 
and compared with virus isolation, RT-PCR and IgM detection. NS1 positivity 
was 91.6% and the authors concluded that it was more sensitive than virus 
isolation.  
Laurent Thomas et al (2010)49conducted study among 70 acute phase 
serum samples and reported NS1 positivity of 67.1%.They concluded that the 
presence of NS1 antigen correlated with plasma viral load and was not 
dependent on the immune status and sampling time. Increased viremia, 
secondary infection and severe disease are associated with NS1 positivity. 
Ivani Bisordi et al(2011)50 conducted a study among 519 serum samples 
and found that NS1 antigen positivity was high (99.3%) suggesting that  NS1 
antigen detection is  highly  suitable tool for early diagnosis and  for monitoring 
the introduction and spread of dengue serotypes. 
WHO stated that MAC-ELISA is the test of choice for rapid diagnosis in 
a single sample, collected after the fifth day of disease. The result was not 
considered as lab confirmation of acute dengue without a convalescent serum 
sample and could be interpreted as recent dengue infection.   
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According to Pan American Health Organization (1994) guidelines,51 by 
day five of illness 80% of cases have detectable IgM antibodies and by day 6-
10, 93-99% of cases have detectable IgM that may persist for over 90 days. 
Chew Then Sang et al52 in 1998 tested 148 patients acute phase serum 
samples and showed that 130 patients were positive for IgM with sensitivity of 
88% and specificity of 91%.      
The ability to detect true positives by IgM ELISA varies from 83.9% to 
98.4% with a 100% chance of detecting true negatives. This range is important 
in secondary dengue patients where IgM antibody titers are only minimal.     
Innis et al (1997)53 observed from his study that the viremia and fever 
ended, as IgM   started to appear. In many of the cases it appeared by the 3rd day 
and disappeared after one to two months. IgM positivity was 78% in acute sera 
and 97% in paired sera. In secondary dengue infections the increase in IgM 
response was slow, mild and lasted only for a short time. 
Prince et al (2011)54 analysed paired serum samples of 145 patients 
collected less than 30 days apart and demonstrated the seroconversion   which 
was used to confirm and classify the infection into 83 primary and 63 secondary 
infections. If both IgM, IgG were positive in acute sample, it indicated that the 
seroconversion had already occurred. 
Dong Mi Hu et al (2011)55 study shows that anti dengue IgM antibody 
positivity was 42.9% on the third day and it rapidly increased to 100% by day 
eight of illness. The sensitivity of NS1 detection during the first seven days 
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ranged from 81.8% to 91.1%.A combination would be suitable in developing 
countries for enhanced diagnosis where dengue is endemic. 
Kassim et al56 tested 208 serum samples  and  the NS1 positivity was 
38.5%, IgM detection rate was 36.1%, combination of antigen and antibody was 
62% and concluded that this combined testing  could increase the efficiency of 
dengue diagnosis. 
Stuart D. Blackshell et al57, suggested that combining the NS1 antigen 
and IgM antibody detection gave  high sensitivity and specificity in  the 
diagnosis of acute dengue infection for patients presenting at different times 
after fever onset. 
Gowri shanker et al58 reported in a study done during an outbreak of 
dengue fever that IgM antibody was positive in all the serum samples that were 
positive for NS1 antigen which were collected within first 5 days of infection. 
The sensitivity of NS1 with IgM detection was higher when compared with RT-
PCR and could be used for early diagnosis.    
Sathish et al59 in his study concluded that  IgM antibodies appear as early 
as three days of dengue viral fever and can persist up to 30–60 days. IgM 
antibodies are useful in providing a provisional diagnosis from a single serum 
sample. 
In a study in Puerto Rico, most patients (80%) by day 5 of illness had 
detectable IgM. Almost all patients (93%) developed detectable IgM 6 to 10 
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days after the onset of fever, and 99% of patients tested positive between day 10 
and 20. (Kuno et al 1991).60    
Schilling et al61 in 2004 studied the sensitivity of IgM detection in paired 
serum samples and correlated with virus isolation. His results showed that the 
samples of patients with primary dengue infection taken during days 1-3 of the 
disease had no IgM antibodies. During days 4-7 and after day 7, IgM antibody 
was detected in 55% and 94%, respectively. In patients with secondary dengue 
infections, less positive IgM was found in samples taken during days 4-7 (47%)  
& after day 7 (78%). 
Anita Chakravarthi (2011)62 conducted a study in  acute phase serum 
samples and observed that the IgM alone were detected in 34% of the samples 
and  NS1 antigen alone was detected in 39.7% of the samples, while 26% were 
positive for both NS1 antigen and  IgM antibody. NS1 antigen was detectable in 
patient sera from Day one onwards and dengue IgM antibody was detected from 
Day three onward and it gradually increased in positivity toward the end of the 
acute illness. From this they concluded that only NS1 antigen can be used 
during the first two days of fever, IgM antibody after the third day of fever and 
no significant difference between both tests from day three to seven. 
IgG antibody is usually detected from day nine of illness in primary 
infection. If it is seen before that it indicates secondary infection with dengue. 
WHO 2009 dengue guidelines says, IgG is used for the detection of recent or 
past dengue infections for  duration of 10 months after infection but they can be 
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present for life time. A fourfold or greater rise in IgG antibodies in acute and 
convalescent sera is the criteria for recent infection. In areas where dengue is 
endemic, it is difficult among infants to exclude the presence of passively 
transferred maternal IgG antibodies or IgG antibodies acquired due to past 
exposure. The problem can be eliminated by confirming the absence of dengue 
virus IgG antibodies in the maternal serum. 
Vaughn et al (1999)63 in his study reported that the IgG capture ELISA 
showed good correlation with HAI assay which is the gold standard to 
differentiate primary and secondary dengue infections. They suggested that IgG 
could be used to discriminate 100% of primary and 96% of secondary dengue 
infections.   
Miagostovich etal64 studied IgG ELISA for dengue and concluded that 
IgG when analyzed by days after onset of symptoms could be reliably 
associated with primary or secondary infections. It can be used to characterize 
the immune response after flavivirus infections.     
Inoues et al (2010)65 stated that IgG detection is simple, rapid and 
sensitive test that can be used in the diagnosis of primary and secondary 
infections.  
Vazquez S et al (2007)66 has shown in his study that ELISA inhibition 
method is used to look for the presence of IgG in serum sample, blood plasma 
and blood samples absorbed onto filter paper permitting the classification into  
primary or secondary dengue infection.  
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3.12. Significance of testing paired serum 
Hunsperger  et al (2009)67 concluded that although demonstration of IgM 
seroconversion in the convalescent sample is taken as a confirmation, presence 
of IgM  in a single specimen collected from a patient with clinical findings 
consistent with dengue, gives a presumptive diagnosis. 
Andrew Falconer et al (2006)68 conducted a study among 100 paired 
serum samples  from suspected dengue cases and  reported  that 37 cases were 
current flavivirus infections if they showed greater than 4-fold increases in 
DENV-specific IgM or IgG  between their  acute  and  convalescent phase  
serum samples. 
3.13. Primary and Secondary infections. 
Primary infection was defined as an IgM positive/IgG negative in the first 
specimen and an IgM negative/IgG negative in the first specimen becomes IgM-
positive/IgG-positive in the second specimen. Secondary infection was defined 
as an IgM-negative/IgG-positive first specimen and an IgM-positive/IgG-
positive second specimen. 
Primary dengue infections usually manifests as a simple fever 
indistinguishable from other viral infections. They are less likely to develop 
severe disease and shock syndrome whereas secondary infections tend to be 
associated with higher morbidity and mortality especially in children. Reliable 
tests for dengue differentiation are essential for patient management and also to 
predict the disease progression and assess mortality especially in severe cases. 
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3.14. Correlation of NS1 in primary and secondary infections 
Duong et al47 noted high NS1 Antigen positivity rate in dengue fever than 
DHF/DSS, in primary than secondary infection. 
Kumarasamy et al69 reported that the NS1 detection sensitivity rate was 
higher in primary dengue (97.3%) than in secondary dengue (70%). 
S D Sekaran et al (2009)70 in their study among 93 acute serum samples 
found that NS1 detection rate was higher in the acute  primary dengue (100%) 
than in the acute secondary dengue (53.5%)  serum samples indicating  that  the 
Dengue antigen assay is a more sensitive assay in the primary acute phase when 
IgM is not detectable. 
Kwoon-Yong Pok et al46 observed decreased sensitivity of NS1 antigen 
testing in secondary dengue infections. Though it was an effective assay, this 
was a disadvantage of NS1 antigen testing. 
Young et al (2000)71 observed that high levels of NS1 were found in 
acute DENV 2 secondary infections and not in convalescent sera. In contrast, 
NS1 was not found in both acute and convalescent sera of   primary infections. 
The presence of high levels of NS1 contributes   significantly to the formation 
of the circulating immune complexes that play a major role in the pathogenesis. 
A study conducted by Koraka et al72 showed that in endemic areas NS1 
antigen in serum samples was low due to the presence of NS1 antigen- anti NS1 
antibody complexes. These complexes were detected much more frequently in 
patients with secondary dengue infections where DHF/DSS is more frequent. 
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To overcome the problem of low NS1 positivity in acute secondary 
infection, acid dissociation of the complexes was suggested, which increased 
the sensitivity of NS1 detection by 25%. Lapphara et al73 observed an increase 
of sensitivity in NS1 detection from 63.2% to 72% with immune complex 
dissociation by acid treatment.  
The haemorrhagic symptoms are more severe in secondary dengue 
infections. The test to discriminate the primary and secondary infection, was 
HAI which was suggested by WHO. But it was very difficult to perform. 
A.Chakravarti et al62. reported that the ELISA itself is an absolute alternative for 
the HAI the gold standard suggested by WHO to discriminate between the 
primary and secondary dengue infection.  
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4. MATERIALS AND METHODS 
4.1. Study place 
This study was conducted at Tirunelveli Medical College Hospital,  
Tirunelveli, among the dengue suspected  paediatric cases admitted in the 
hospital. 
4.2. Study period 
The study period was from August 2011 to January 2012. 
4.3. Ethical consideration              
Written consent to participate in the study was obtained from the 
children’s parents or guardians after explaining the full study.  This study was 
reviewed and approved by Institutional Ethical Committee, Tirunelveli Medical 
College, Tirunelveli before the commencement of the study. 
4.4. Study population 
A total of 110 blood samples were collected from sixty five children, 45 
had paired sample. 
4.4.1. Inclusion criteria 
1. Paediatric patients  (0-12years) 
2. Children admitted with acute febrile illness with two or more of the 
following features of WHO criteria- headache, myalgia, retro orbital pain, 
rash, haemorrhagic manifestations and thrombocytopenia.  
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4.4.2. Exclusion criteria 
1. Febrile cases without the above features  
2. Haemorrhagic conditions without symptoms of Dengue fever.  
3. Patients with clinical evidence of respiratory tract infection, urinary tract 
infections, acute diarrheal disease, injury, sepsis, or other apparent causes 
of fever were excluded.  
  4.5. Sample collection 
Clinical data was collected from all children admitted with fever in the 
paediatric ward. Blood sample was taken from children who had fever with one 
or more of the following features like thrombocytopenia, haemorrhagic 
manifestations like epistaxis, bleeding gums, haematemesis, malena, petichial 
haemorrhages, features of leaky capillaries like pleural effusion, ascitis  seen on 
X’ray or ultrasound  and  haematuria on urinalysis. 
Blood samples were collected from the children with above mentioned 
clinical picture of dengue infection after taking written consent from their 
parents. Three to 4 ml of whole blood was drawn by the intravenous route with 
aseptic precautions & transferred to a sterile leak proof glass container. The 
blood samples were transported to the lab immediately with proper labeling 
(name of the patient, identification number and date of collection) 
Patients were advised to come to the paediatric outpatient clinic after 2 
weeks of discharge for review and the second sample was 
collected.(convalescent sample) 
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4.6. Sample processing and storage 
In the lab, the samples were kept at room temperature (20-25oC) for at 
least 30 minutes. Then serum was separated by centrifuging at 2000 rpm for 3 
minutes and stored at -20oC until testing, in a sterile vial. Icteric or lipemic sera 
exhibiting haemolysis were rejected. Proper biomedical waste management was 
followed throughout the study. 
For all the 65 samples collected in the acute phase, NS1 antigen and IgM 
ELISA was performed. 
For the 45 samples collected in the convalescent phase IgM ELISA was 
performed. For the same 45 samples IgG was tested in the acute sample 
(collected earlier) and convalescent sample. 
4.7.ELISA kits  
Dengue Early ELISA for NS1 Antigen detection, IgM Captue ELISA, 
IgG Capture ELISA were purchased from  Panbio pty Ltd, Brisbane,Australia. 
The kits were stored at 2-80 C.   
4.8.Equipments   
Deep Freezer (-20Oc), Incubator, ELISA washer and reader (Bio Rad, 
France), Accurate micropipettors with disposable pipette tips (5-1000µl 
capacity) 
4.9. Methods 
      All the samples were tested for NS1 antigen, IgM and IgG in the 
Microbiology laboratory, Tirunelveli Medical College Hospital, Tirunelveli. 
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4.9.1. Dengue Early ELISA for NS1 Detection  
4.9.1a. Principle 
NS1 antigen, when present in the serum, binds to anti-NS1 antibodies 
coated on the surface of the micro wells. Horsh Radish Peroxidase conjugated 
Anti NS1 Monoclonal antibody hydrolyses the Tetra Methyl Benzidine 
substrate and colour development indicates of the presence of dengue NS1 
antigen in the samples.  
 4.9.1b.Serum predilution        
All the reagents provided in the kit and the samples were brought to room 
temperature. 
The controls, positive and negative, Cut-off calibrators and the samples 
were diluted in test tubes. To 75 mic.lit of serum, 75 mic.lit of sample diluent 
was added and mixed. The final dilution was 1:2. 
4.9.1c.ELISA procedure 
1. 100mic.lit of diluted samples and controls (one positive control, one 
negative control, 3 cut off calibrators) were added to their respective 
microwells. 
2. The microtitre plate was covered and incubated for 1hour at 37 deg. 
Centigrade. 
3. After washing 6 times by diluted wash buffer, 100µl of HRP conjugated 
Anti NS1 Mab is added. 
4. The plate was covered and incubated at 37 o C. for 1 hour.  
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5. The assay plate was washed 6 times. After that 100µl TMB per well was 
added and incubated for 10min at room temperature. 
6. 100mic.lit stop solution was added to stop the reaction and the 
absorbance was read at 450nm and 600-650nm. 
The average value of the three cutoff calibrators were calculated and 
multiplied by 0.66 to get the cutoff value. 
The absorbance OD of the sample was divided by the value got in the 
previous step to get the index value. 
Panbio units were calculated by multiplying the index value by 10. 
4.9.1d.Interpretation of results 
     Index value     Units(Panbio) Results 
Less than 0.9  Less than 9 Negative 
0.9 to1.1 9 to11 Equivocal 
More than 1.1 More than 11 Positive 
 
4.9.1e.Test validity 
Calibration factor: 0.66 
Negative absorbance: <0.300 
Cut-off value: > 1.5 x Negative absorbance 
Positive control/cutoff Ratio: 2.0-9.0 
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4.10. Dengue IgM Capture ELISA – MAC ELISA 
4.10.1a.Principle 
      IgM antibodies, if present, combine with anti IgM antibodies coated on 
the surface of the micro wells. HRP conjugated monoclonal antibody- 
concentrated pool of dengue 1-4 antigen complex hydrolyses the TMB substrate 
and colour development indicates of the presence of IgM antibodies in the test 
sample. 
4.10.1b.Serum predilution      
 All the reagents provided in the kit and samples were brought to room 
temperature. 
The positive control, negative control, cutoff calibrators and the samples 
were diluted (1:100) in test tubes. To 10 mic.lit of serum, 1ml sample diluents 
was added and mixed well. 
4.10.1c.ELISA procedure 
1. Ten microlitre of antigen was added to 2.5ml of antigen diluents and 
mixed.  
2. The diluted antigen was mixed with an equal volume of MAb Tracer 
(Horse Radish Peroxidase conjugated Monoclonal Antibody Tracer) in a 
separate test tube and left at room temperature.  
3. 100 mic.lit samples and controls (one positive control, one negative 
control, 3 cut-off calibrators) were added to the assay plate (anti human 
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IgM coated micro wells). The plate was covered and incubated for 1 hr at 
37 deg. Centigrade. 
4. The assay plate was washed 6 times. 100mic.lit of antigen – Mab solution 
was transferred per well to the assay plate.  
5. The plate was covered and incubated for 1hr at 37 deg C. 
6. The assay plate was washed 6 times. After that 100mic.lit TMB per well 
was added and incubated at room temperature for 10 minutes. 
7. The reaction was stopped with 100 mic.lit stop solution and the 
absorbance was read at 450nm and 600-650nm. 
The average value of the three cutoff calibrators were calculated and 
multiplied by 1.14 to get the cutoff value. 
The absorbance OD of the sample was divided by the value got in the 
previous step to get the index value. 
Panbio units were calculated by multiplying the index value by 10. 
4.10.1d.Interpretation of results 
Index value Units (panbio) Results 
Less than 0.9 Less than 9 Negative 
0.9 to1.1 9 to11 Equivocal 
More than 1.1 More than11 Positive 
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4.10.1e.Test validity 
Calibration factor: 1.14 
Negative absorbance :< 0.400 
Cut-off value :> 1.5 x Negative absorbance 
Positive control/cut-off Ratio: 1.1-7.0 
4.11. Dengue IgG capture ELISA 
4.11.1a.Principle 
IgG antibodies, if present; combine with anti IgG antibodies coated on the 
surface of the micro wells. HRP conjugated monoclonal antibody- concentrated 
pool of dengue 1-4 antigen complex hydrolyses the TMB substrate and colour 
development indicates of the presence of IgG antibodies in the test sample. 
Serum antibodies of the IgG class, when present, combine with anti-
human IgG antibodies coated on the surface of the polystyrene micro wells. A 
concentrated pool of dengue 1-4 antigens is diluted with diluents. HRP-
conjugated monoclonal antibody is added to the diluted antigen allowing the 
formation of antigen MAb complexes. After washing, complexed antigen MAb 
is added to the assay plate. These Antigen-MAb complexes then bind to the 
serum dengue specific IgG antibodies. After incubation the micro wells are 
washed and a colourless TMB chromogen is added. The substrate is hydrolyzed 
by HRP if present, and the chromogen turns blue. After stopping the reaction 
with acid, the TMB turns yellow. Colour development is indicative of the 
presence of anti-dengue IgG antibodies in the test samples. 
44 
 
4.11.1b.Serum predilution 
The positive control, Negative control, cutoff calibrators and the patients 
samples were diluted (1:100) in test tubes. To 10µl of serum 1000 µl sample 
diluents was added and mixed well. 
4.11.1c.ELISA procedure 
1. Antigen dilution 1:250. For this 10 mic.lit of antigen was diluted with 
2.5ml of antigen diluent. This was sufficient for 5 strips. (0.5ml of diluted 
antigen required per strip)    
2. The diluted antigen was mixed with an equal amount of MAb Tracer in a 
separate test tube and left at room temperature for 1hr. 
3. 100µl of diluted samples and controls were added to their respective wells 
of the assay plate. The plate was covered and incubated for 1hr at a 
temperature 37 deg C. 
4. The assay plate was washed 6 times with diluted wash buffer and 100 
mic.lit of antigen-MAb solution, prepared in step- 2 was transferred to 
each well of the assay plate. 
5. The plate was covered and incubated for 1hr at 37 deg C. 
6. The assay plate was washed 6 times. 100 mic.lit TMB per well was added 
and incubated for 10 min at room temperature. 
7. The reaction was stopped with 100mic.l stop solution and the absorbance 
of each well was read at 450nm with reference filter of 600-650nm. 
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   The average value of the three cutoff calibrators were calculated and 
multiplied by 1.00 to get the cutoff value. 
The absorbance OD of the sample was divided by the value got in the 
previous step to get the index value. 
Panbio units were calculated by multiplying the index value by 10. 
4.11.1d.Interpretation of results 
Index value Panbio Units Results 
Less than1.8 Less than18 Negative 
1.8 to 2.2 18 to 22 Equivocal 
More than 2.2 More than 22 Positive 
 
4.11.1e.Test validity 
Calibration factor: 1.00 
Negative absorbance :< 0.300 
Cut - off value: > 1.5 x Negative absorbance 
Positive control/cut- off Ratio: 1.1-4.0 
Statistical analysis 
Results were analyzed for the parameters like mean, median and 
percentages. Parametric tests like ‘Z’,‘t’ and non – parametric test like ‘χ2’ test, 
logistic regression test were used analyze the differences wherever applicable. 
Statistical analysis was done using SPSSversion16.software. 
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5. RESULTS 
5.1 The Study Group 
 A total of 65 children admitted in the paediatric ward of Tirunelveli 
medical college hospital with a clinical suspicion of dengue infection were 
included in the study. The period of study was from August 2011 to January 
2012. The study was completed before the recent outbreak of dengue at 
Tirunelveli district.  
5.2 Age and gender of the study group 
Table –1 Age and gender wise distribution of cases under study 
S.No Age (years) Male Female Total 
1 0-4 10(67%) 5(33%) 15(23%) 
2 5 – 8 17(61%) 11(39%) 28(43%) 
3 9 – 12 14(64%) 8(36%) 22(34%) 
Total 41(63%) 24(37%) 65(100%) 
 
Table-01 shows age and gender wise distribution of cases under study. Of 
the 65 cases, 41(63%) were male and 24(37%) were female. The age of the 
children were further categorized into three groups as follows, 0-4, 5-8 and 9-12 
years. The most common age group that participated in this study was between 
 5 and 8 years constituting about 43% .More number of male patients were seen 
in all age groups. 
However in comparison to the total male and female cases included under 
the study, there was no significance (p 
age in the groups.  
Figure 1 Age and Gender wise distribution of cases under study
Figure 2 Gender wise distribution of cases under study (in percentage)
37
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5.3. Monthwise distribution of admission of study group 
Table 2 Month wise distribution of cases 
Sl.No Month of admission Number of cases Percentage 
1 August 4 6.2% 
2 September 5 7.7% 
3 October 10 15.4% 
4 November 14 21.5% 
5 December 15 23.1% 
6 January 17 26.1% 
 
The above table shows the month wise distribution of cases admitted in 
the hospital during the study period. There was an increase in the number of 
cases during October (15.4%) compared to the previous two months. The cases 
then gradually increased and was on the rise during November (21.5%), 
December (23.1%) and January (26.1%). This corresponds to the monsoon 
season of this place.  
  
 Figure 3 Month wise distribution of cases under study
 
4
0
2
4
6
8
10
12
14
16
18
August September
N
u
m
be
r 
o
f c
a
se
s
49 
 
5
10
14
15
October November December
Months
 
 
17
January
50 
 
5.4 Symptoms of the study group 
Table-03 and Fig-04 represents the clinical symptoms of the study 
population.  
Table 3 Symptoms of the cases under study (n=65) 
S.No. Symptoms Number of cases Percentage 
1 Fever 65 100 
2 Vomiting 51 79 
3 Haemorrhagic 
manifestations 
35 54 
4 Abdominal pain 34 52 
5 Myalgia 26 40 
6 Rashes 4 6 
7 Retro orbital pain 2 3 
 
Next to the predominant symptom of fever (100%), vomiting was seen in 
51(79%) cases. Haemorrhagic manifestations like petechiae, bleeding gums, 
haemetemesis, malena, haematuria and subconjunctival haemorrhage were seen 
in 35(54%) cases.  
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Abdominal pain which may be due to gastrointestinal bleeding, liver 
injury and hepatomegaly in dengue were observed in 34(52%) cases. Myalgia 
was observed in 26(40%) cases. 
 Rashes were noted in 4(6%) cases. Retro orbital pain which is generally 
considered as a cardinal feature of dengue fever was noted only in 2(3%) cases 
in this study. 
Figure 04 Symptom wise distribution of cases under study 
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5.5. Lab findings of the study group 
Table  4 Laboratory findings of the cases under study (n=65) 
S.no Investigations Findings No. of cases (%) 
1 Haemoglobin < 10 gm/dl 10(18%) 
>10 gm/dl 55(82%) 
2 WBC 
(/cumm) 
<4000 cells 10(18%) 
>4000 cells 55(82%) 
3 HCT <35 17(26%) 
>35 48(74%) 
4 Platelets 
(/cumm) 
<50000 31(48%) 
>50000 34(52%) 
5 LFT Elevated 10(18%) 
6 Chest X ray Pleural effusion 3(5%) 
 
7 
 
Ultrasonagram 
Ascites 7(11%) 
Hepatomegaly 6(9%) 
Gall bladder wall 
thickening 
8(12%) 
Pleural effusion 16(25%) 
 
Various lab investigations like Haemoglobin (Hb), WBC, Hematocrit 
(HCT), Platelet counts (PLT) and Liver function tests (LFT) were analysed. 
53 
 
Chest Xray (CXR) was evaluated for pleural effusion. Ultrasonogram (USG) 
was performed to look for ascites, hepatomegaly, and gall bladder wall 
thickening suggestive of acalculous cholecystitis and pleural effusion. 
10(18%) cases had Hb less than 10 gm/dl and 55(82%) had more than 10 
gm / dl. 55(82%) cases had a WBC count of more than 4000 cells and 10(18%) 
had less than 4000 cells. HCT was more than 35 in 48(74%) cases and less than 
35 in 17(26%) cases.  
PLT was less than 50,000 in 31(48%) cases and more than 50000 in 
34(52%) cases. None of the patients had platelet count of more than 1,00,000 
indicating that all had thrombocytopenia. In LFT, enzymes were found elevated 
in 10(18%) cases.  
Pleural effusion was seen by CXR in 3(5%) cases and in 16(25%) cases 
by using ultrasound. Hepatomegaly was seen in 6(8%) cases and gall baldder 
thickening suggestive of acalculous cholecystitis was seen in 8(12%) cases in 
USG analysis. 
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5.6 Day of fever on admission 
Table 5 Fever in days of the study population (n=65) 
Fever 
in days 
No. of cases 
 
Total Male Female 
2 2 3 5(8%) 
3 4 3 7(11%) 
4 8 3 11(17%) 
5 12 6 18(28%) 
6 4 3 7(11%) 
7 11 6 17(26%) 
Total 39 26 65 
 
Table-05 shows the day of fever, on which the patients were admitted and 
samples were collected for dengue investigations. 41(64%) cases were admitted 
within 5 days of onset of fever of which 26(40%) cases were males. Around 
50% of cases were admitted between 3 to 5 days. After 5 days only 24 (37%) 
cases were admitted of which 11 were male and 6 were females. 
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Figure 5 Fever in days of the study population 
 
5.7 NS1, IgM ELISA Test Results 
All the 65 samples collected during the acute phase of fever were tested 
for NS1 antigen and IgM antibody by ELISA.  
Table 6 Test Results of acute phase samples 
Total samples 
tested 
IgM/NS1/Both 
Positive 
Negative 
65 46 19 
 
Of the 65 samples , 46(71%) tested positive for  NS1, IgM or both. 19 
(29.2%) samples tested negative for both the tests in the acute phase sera.  
  
 Table 7. NS1 / IgM ELISA results (n=65)
Only NS1 positive
Only IgM positive
Both 
Total positive
 
Only NS1 antigen was positive in 5 samples, only IgM was positive in 26 
samples and both were positive in 15 samples.
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6 Tests Results – NS1/IgM (n=65) 
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5.8. Fever Correlation with Test results 
Table 8 Correlation of fever and results of NS1 and IgM among study 
population (n=65) 
Fever 
in days 
No. of samples 
tested 
NS1 
Positive 
NS1 
Negative 
Percentage 
of NS1 
Positive 
Percentage  
of IgM 
Positive 
IgM 
Pos 
IgM 
Neg 
IgM 
Pos 
IgM 
Neg 
2 5 0 0 3 2 0 60 
3 7 2 2 1 2 57 43 
4 11 4 0 6 1 27 91 
5 18 3 2 7 6 28 56 
6 7 2 0 3 2 29 71 
7 17 4 1 6 6 29 59 
TOTAL 65 15 5 26 19 31 63 
 
 Table – 08 correlates the day of fever and the test results among study 
population.  
Of the total 65 samples that were collected and tested for NS1 and IgM, 
20 were positive for NS1, 41 for IgM, 15 for both and 19 samples tested 
negative for both. Only NS1 was positive in 5 samples and only IgM was 
positive in 26 samples. 
Of the 5 samples collected on day two of fever, 3 were positive for IgM, 
none was positive for NS1 and 2 were negative for both.  
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Of the 7 samples collected on day three of fever, 4 were positive for NS1, 
3 were positive for IgM, 2 were positive for both and 2 were negative for both 
tests.  
Of the 11 samples collected on day four, 4 tested positive for NS1, 10 for 
IgM, 4 were positive for both and 1 was negative for both NS1 and IgM.  
Maximum number of samples was obtained on day five of fever. Of the 
18 samples collected, 5 were positive for NS1and 10 for IgM. 3 samples tested 
positive for both and 6 were negative for both tests.  
On day six of fever, 7 samples were obtained. Of which, 2 were positive 
for NS1 and 5 for IgM. 2 samples tested positive for both and 2 were negative 
for both.  
Of the 17 samples collected on day seven of fever 5 was positive for NS1 
and 10 for IgM. 4 were positive for both NS1 and IgM and 6 were negative for 
both. 
More number of IgM positive cases were observed from day four 
onwards. Out of the 41 IgM positive cases, 35 had more than four days of fever. 
Statistical analysis done by binary logistic regression method showed that 
NS1 detection in acute phase is not significant (p >0.05) and IgM detection is 
significant (p <0.05) 
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Figure 7 Correlation of fever and results of NS1 and IgM among study 
population.  
 
5.9 Significance of Testing Paired Sera 
 A second sample could be collected from 45 patients for whom IgM 
and IgG ELISA was performed.  For the same 45 patients, IgG ELISA was 
performed for the acute phase samples which had been collected earlier. 
  Of the 45 samples, 12 had tested negative for NS1/IgM/IgG in the 
first sample. The following table analyses the results of the 12 negative samples.  
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Table 9 Analysis of paired sera for the initially negative samples (n=12) 
Sl.No. 
Sample 1 
(Acute sera) 
Sample 2 
(Convalescent sera) Dengue result 
IgM IgG IgM IgG 
1 Neg Neg Neg Neg Negative 
2 Neg Neg Neg Neg Negative 
3 Neg Neg Neg Neg Negative 
4 Neg Neg Neg Neg Negative 
5 Neg Neg POS Neg Seroconversion Positive 
6 Neg Neg POS Neg Seroconversion Positive 
7 Neg Neg POS Neg Seroconversion Positive 
8 Neg Neg Neg POS Positive 
9 Neg Neg Neg POS Positive 
10 Neg Neg Neg POS Positive 
11 Neg Neg Neg POS Positive 
12 Neg Neg Neg POS  
(Low titre) 
Past infection 
  
 Out of the 12 samples which were initially negative for IgM and NS1, 
4 cases gave negative results for NS1, IgM, and IgG in the second sample also. 
So they were declared dengue negative cases.  
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 Of the remaining 8 cases, three were positive for IgM (seroconversion) 
and were now declared as dengue confirmed cases. 
 Four cases were positive for IgG in the second sample and they were 
declared as secondary infection cases. 
 The remaining one case showed low IgG titre in comparison to the 
first IgG value and was declared as past infection with dengue. 
 Significance of using paired sera was analyzed by testing the 12 
samples which were negative initially. The results are shown in Table - 09. 
Paired serum analysis is found to be statistically significant (p<0.05) in the 
diagnosis of dengue infection.  
5.10 Primary and Secondary dengue infection 
The criteria used for classifying Primary and Secondary dengue infection 
were as follows. Primary infection was defined as an IgM positive/IgG negative 
in the first specimen and an IgM negative/IgG negative in the first specimen 
becoming IgM-positive/IgG-positive in the second specimen.  
Secondary infection was defined as an IgM-negative/IgG-positive first 
specimen and an IgM-positive/ IgG-positive second specimen. 
 Table-10 gives the OD values of IgM and IgG in the acute and 
convalescent sera of the 45 samples with which they were classified into 
primary and secondary dengue infection. 
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Table – 10. Analysis of acute and convalescent phase sera (n=45) 
 
Sl. 
No. 
Sample 1 
N0 
Sample 1 
(OD value) 
Sample 2 
N0 
Sample 2 
(OD value) 
 
Type of 
Infection 
IgM 
cutoff 
value 
0.488 
IgG 
Cutoff 
value 0.247 
IgM  
cutoff value 
0.488 
IgG  
 cutoff 
value 0.247 
1 5 0.18 0.06 16 1.167 0.855 Primary 
2 4 2.4 2.36 16 2.428 2.414 Secondary 
3 4 2.42 2.4 18 0.504 2.365 Secondary 
4 7 0.277 0.202 18 0.243 0.277 Negative 
5 5 1.263 0.486 19 0.46 0.365 Primary 
6 7 0.51 0.814 19 2.167 2.412 Secondary 
7 6 2.43 2.419 18 2.423 2.425 Secondary 
8 2 2.48 2.46 15 2.366 2.499 Secondary 
9 7 2.557 2.489 18 2.495 2.426 Secondary 
10 2 2.055 0.237 13 0.27 0.279 Primary 
11 6 0.285 0.113 21 0.381 0.811 Secondary 
12 5 2.446 0.046 16 2.369 0.871 Primary 
13 5 0.146 0.164 16 0.224 0.407 Negative 
14 7 0.753 1.524 17 1.411 1.763 Secondary 
15 5 2.441 0.795 16 2.432 2.353 Secondary 
16 5 2.502 0.526 15 2.502 0.336 Primary 
17 4 2.566 0.091 18 2.447 0.496 Primary 
18 7 2.424 0.089 16 2.436 0.501 Primary 
19 7 0.373 0.026 22 0.224 0.33 Negative 
20 5 2.436 1.193 22 1.826 1.521 Secondary 
21 3 0.637 0.206 16 1.327 0.029 Primary 
22 4 2.3 0.147 16 2.471 1.337 Primary 
23 3 2.134 2.401 17 1.135 2.271 Secondary 
24 7 2.498 2.469 18 0.34 0.169 Secondary 
25 5 1.011 0.315 18 0.386 0.153 Primary 
26 7 2.346 1.497 18 1.426 2.55 Secondary 
27 5 0.2 0.783 18 0.31 0.719 Secondary 
28 3 1.293 0.146 18 2.54 0.308 Primary 
29 7 0.371 0.416 15 0.232 0.022 Negative 
30 2 0.267 0.051 17 2.441 2.382 Primary 
31 7 0.332 0.067 17 1.849 0.276 Primary 
32 5 2.482 2.497 19 2.4 2.493 Secondary 
33 5 2.519 2.606 18 2.364 2.344 Secondary 
34 6 2.363 2.364 18 2.42 2.415 Secondary 
35 6 0.382 1.073 12 0.196 0.066 Secondary 
36 5 0.244 0.045 16 0.524 0.594 Past infection 
37 7 2.524 2.515 15 2.407 0.341 Secondary 
38 6 2.306 2.44 21 2.423 2.416 Secondary 
39 6 2.437 0.044 22 2.449 0.202 Primary 
40 5 1.201 0.119 12 2.519 0.196 Primary 
41 4 2.576 0.138 17 0.316 0.126 Primary 
42 5 2.406 2.376 17 2.364 2.385 Secondary 
43 7 2.472 2.262 20 2.456 2.087 Secondary 
44 6 2.463 0.056 17 2.534 0.54 Primary 
45 4 2.466 2.476 16 2.067 2.349 Secondary 
N0 = Number of days from the start of the symptoms. 
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 The following table consolidates the primary and secondary dengue 
cases. 
Table 11 Primary and Secondary dengue infection 
Total samples Primary Dengue Secondary Dengue 
45 17 23 
 
 Of the 45 samples, 17 were declared as primary Dengue and 23 were 
declared as secondary Dengue infection 
5.10.1   NS1 in Primary and Secondary dengue infection 
Table – 12 . Correlation of NS1 with primary and secondary infection 
Type of 
infection 
Total 
cases 
NS1 
p value 
Positive Negative 
Primary 17 10 7 
0.013(<0.05) 
Secondary 23 5 19 
   
 Out of 17 lab confirmed primary dengue cases, NS1 was positive for 10 
(59%) cases and out of the 23 secondary cases it was positive in only 5(22%) 
cases. This shows that NS1 is more sensitive in finding primary cases (p <0.05).  
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5.11.2   Clinical findings in Primary and Secondary dengue infection 
 Table-13 analyses various factors like age, sex, haematocrit, platelet 
count, WBC count and USG findings in relation to primary and secondary 
dengue infections. 
Table – 13. Clinical manifestations of primary and secondary infections 
CHARACTERS 
PRIMARY 
INFECTION 
SECONDARY 
INFECTI0N 
p  
value 
 
 
Age in years 
 
0 – 4 
Male 4 3 NA 
Female 1 2 NA 
 
5 – 8 
Male 3 8 NA 
Female 2 6 NA 
 
9 – 12 
Male 4 3 NA 
Female 3 2 NA 
 
Sex 
Male 11/25    (44%) 14/25   (56%) >0.05 
Female 6/16     (38%) 10/16   (62%) 
Platelet count < 50000/cu.mm 7/21     (41%) 14/21 (58%) <0.05 
>50000/cu.mm 10/20   (59%) 10/20   (52%)  
Haemorrhagic manifestations 8/22      (47%) 14/22   (58%) >0.05 
Hct >35 12/33   (36%) 21/33   (64%) <0.05 
WBC <4000/cu.mm 2/5       (40%) 3/5       (60%) >0.05 
USG Pleural effusion 3/13      (23%) 10/13   (77%) <0.05 
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 Out of 40 cases, 19(46%) were in the age group of 5 to 8. In this group 
14(74%) had secondary dengue infection.  More number of males was seen in 
both primary and secondary infection compared to females. But statistical 
analysis using Fisher exact test showed that the difference was not significant 
(p>0.05).  
 21(51%) cases had a platelet count of less than 50000 cells. Of which 
14(58%) cases were seen in secondary infection which is statistically significant 
(p <0.05). 
 Haemorrhagic manifestations were more common in secondary infection 
but was not statistically significant (p>0.05). 
 21 out of the 33(64%) cases had a haematocrit of more than 35 in 
secondary infection. Analysis by paired t test showed this to be significant 
(p<0.05).  
 Three out of the 5(60%) secondary dengue cases had WBC of less than 
4000. More cases had pleural effusion in secondary infection and was 
statistically significant (p<0.05).  
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6. DISCUSSION 
Dengue is an emerging public health problem in India. In the present 
study 65 children, who were admitted in the paediatric ward of Tirunelveli 
Medical College with a clinical suspicion of dengue virus infection were 
analyzed.  
6.1 Age and Gender 
 Amongst the fever cases admitted, 65 children fulfilled the inclusion 
criteria and were included in the study. Majority of the cases were between 5-8 
years. Similar finding was reported by Nisalak et al30 (5-9yrs) and Kabra et al33 
(8 years). 
In the present study the male to female ratio was 1.7:1. Similar pattern 
was seen in the analysis of 2006 dengue outbreak in North India by 
Chandrakanta et al74 (1.6:1) and Mittal et al75(1.3:1). Male children were more 
commonly affected than female children in the studies of   Neeraja et al 19 (2:1) 
and Aggarwal et al36 (3:2) whereas Maria Guzman et al 2(1:1.4), Kabra et al33 
and Ole Wichman et al32 (0.96:1) reported in their studies that female children 
were slightly more affected than male children. But overall, a review of reported 
literature shows no sex predilection for the disease Statistical analysis revealed 
that there was no association between age and gender in the present study.  
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6.2 Seasonal Distribution 
 The study was done from August 2011 to January 2012. Analysis of the 
data was done for each month to identify the seasonal variance of dengue 
infection. A gradual increase in the occurrence of cases was seen from 
September with a peak in December and January which corresponds to the 
monsoon rainfall of this region. This results in stagnation of water, which 
facilitates vector breeding. Between November and January there were 46 
(70.7%) cases enrolled in this study. Similar studies indicating the correlation 
between emergence of dengue and monsoon was reported in South India by 
S.C. Tewari et al6 and Singh J et al28   in Central India by PM Ukey et al, 18 in 
Karnataka by Aswini kumar et al76 and in Karachi by Khan et al.77 This finding 
indicates that preventive measures play an important role during water 
stagnation periods, in the fight against dengue infection.  
6.3 Clinical Symptoms of the cases under study 
The most common presenting symptom in this study was fever (100%) 
which was the essential criteria for inclusion in the study. Various studies done 
in India by Aggarwal et al,36  Chandrakanta et al,74 Mittal et al75 and have stated 
fever as the commonest presenting symptom. 
Vomiting which is a warning sign of severe infection was seen in 
51(79%) cases. It was observed in 83% of cases by Narayanan et al,34 Retgeri et 
al38 and 82% of cases similar to the present study. Aggarwal et al36 has noted 
lesser incidence of 68% in his study. 
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In the present study abdominal pain was seen in 34 (52%) cases similar to 
Batra et al78 (52%). Abdominal pain in 61% of dengue infected cases was 
observed in a study done by Ratgeri et al.38 Aggarwal et al36 and Narayanan et 
al34 observed abdominal symptoms of 49% & 23% respectively in their studies. 
Khan et al77 has reported that abdominal pain could be due to liver injury, 
gastro intestinal bleeding and acalculous cholecystitis or capsulitis caused by 
the dengue virus. It is important to remember that infections that cause fever 
and gastro intestinal symptoms like enteric fever, leptospirosis, enteroviral 
infections are endemic in India and may often lead to a delay in dengue 
diagnosis. Hence it is suggested that all forms of dengue fever should be 
included in the differential diagnosis of patients with fever and gastrointestinal 
symptoms. 
Next common clinical symptom was haemorrhagic manifestations like 
epistaxis, bleeding gums, haematemesis and malena due to plasma leakage and 
increased vascular permeability which was seen in 35(54%) cases in the present 
study. Haemorrhagic manifestation was noticed in more than 30% of the cases 
by Aggarwal et al,36 in 40% by Ratgeri et al38 and in 66.1% by Narayanan et 
al.34  
Maculopapular rash, which is an important finding in dengue infection, 
was seen in only 6% of cases in this study. Various authors have reported skin 
rashes ranging from 22% to 60% in their studies. 37.5% children in a study by 
Chandrakanta et al74 had skin rash, while 24.4% was observed by Batra et al78 
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and 26% by Mittal et al.75 The low incidence in this study may be due to 
difficulty in identifying the rash in dark skin complexion seen in this part of the 
country.  
Retro orbital pain which is included in the clinical diagnosis of dengue 
infection by WHO, was seen in only 3% of cases. Neeraja et al19 (7%) and 
Narayanan et al34 have reported an incidence of 12% of cases having retro 
orbital pain in their study. Since a good number of patients were in the age 
group of less than 8 years in the present study, it was difficult to elicit the 
history.  
6.4 Lab Investigations  
Various lab investigations like Haemoglobin (Hb), WBC, Hematocrit 
(HCT), Platelet count (PLT), Liver function tests (LFT) and Imaging techniques 
like Chest Xray and USG reports were analyzed. 
Haemoglobin and haematocrit which was collected at the time of 
admission showed that 78% of the cases had haematocrit of more than 35. This 
value is taken as a haemoconcentrated state as per Balasubramanium et al80 
defining the severity of the problem. Haemoconcentration has been reported in 
the studies of Aggarwal et al36 (42%) and Narayanan et al34 (24.1%). Patients 
with haemoconcentration were monitored with serial haematocrit taken once in 
2 hours, according to WHO guidelines and were aggressively managed.  
A platelet count of less than 1x105 cells indicating thrombocytopenia is 
one of the criteria in the clinical diagnosis of dengue fever. This is an important 
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and cost effective investigation in dengue suspected cases, where ready access 
to viral culture or identifying antigen, antibody markers are not available. In this 
study all patients had a platelet count of less than 1x105 cells, of which 48% of 
cases had a count of less than 5x104 cells. Low platelet counts were reported by 
Narayanan et al34 (43%) and Aggarwal et al36 (69%) in their studies. 
Various studies have reported that leukopenia of less than 4x103 is a 
significant finding in DHF and DSS ( Kabilan et al39). In the present study total 
leucocyte count of less than 4x103 was observed in 18% of cases. Similar results 
have been shown by Aggarwal et al36 (15%) and Retgeri et al38 (24%).  
Features of plasma leakage like pleural effusion, ascites, hepatomegaly 
are cardinal features in DHF/DSS. In the present study pleural effusion was 
picked up by chest X-ray in 3(5%) cases and by ultrasonogram in 16(25%) 
cases. Similar results of USG being a superior diagnostic test for detecting 
pleural effusion has been reported by Balasubramanium et al80 (23%). 
Gall bladder wall thickening due to acalculus cholecystitis was noted in 
12% of cases which was much lower than the study of Balasubramanian et al80 
(32%). 
6.5 Test Results 
The gold standard in confirming dengue is by viral culture. But it is a 
time consuming and technically demanding procedure which may not be 
available in many public health hospitals in developing countries. So antigen- 
antibody detection is the cornerstone in the diagnosis of early dengue infection.  
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Antigen detection by NS1 capture ELISA can be done as early as the first 
day to as late as eighteenth day of onset of symptoms (Xu et al 41) with 
sensitivity as good as RT-PCR. 
In the present study, out of the 65 suspected dengue cases, 45 (70.8%)  
tested positive for  NS1 or IgM or both. 19 (29.2%) samples tested negative for 
both the tests in the acute phase sera.  
Of the 65 samples tested, NS1 was positive in 20(31%) cases. Many 
authors like Ivani Bisardi et al50 (99.3%), Chua et al48 (91.6%), Laurent Thomas 
et al49 (67.1%) have stated that the incidence of detecting NS1 antigen is more 
sensitive in acute phase samples. 
In the present study more NS1 positive cases were seen in day 5 and 7 
with five cases on each day. 
Mini P Singh et al43 considered NS1 testing to be useful till 3rd day of 
illness and Dussart et al42 observed NS1 to be useful till 4 days of the illness in 
the diagnosis of dengue infection. Both the authors did not find it to be useful 
beyond the 5th day of illness. 
Alcon et al40 found that NS1 can be detected upto 10 days, with higher 
sensitivity on day 4 & 5. Xu et al41 found that NS1 can be found up to 18 days 
with peak at days 6-10. 
However in the present study the sensitivity of detection of NS1 antigen 
was found to be low, in first 5 days of illness. Studies done by many authors 
have reported the incidence of detecting NS1 antigen in the acute phase 
72 
 
samples. Shrivastava et al45(16%), Koraka et al72 (18%), Kulkarni et al79(30%), 
Remirez et al81(30%), Kassim et al56 (32.2%) and Anita Chakravarthi et 
al62(39.7%)]. The lower detection rate may be due to low viremic index, early 
immune complex formation or due to the serotypes DENV 2 & 4 which was not 
confirmed in the study. 
IgM antibody appears as early as 3 days and reaches a peak in 2 weeks 
and remains positive for 2 to 3 months. In the present study, 41(63%) cases 
tested positive for IgM antibody. More number of IgM positive cases were seen 
from day 4 onwards compared to NS1 antigen. Testing of IgM after 4 days was 
found to be significant in the present study. Similar reports by many other 
studies like Sang et al52 (3days) and Innis et al 53(4 days) implies the 
significance of IgM antibody testing after day 3 in diagnosis of acute dengue 
infection.  
From this study we could assess that NS1 was sensitive in diagnosing 
31% of cases and this increased to 71%, by a margin of 40% when combined 
with IgM antibody test in diagnosing dengue between days 2 and 7. 
Substantial increase in sensitivity was obtained by Duong et al47 (57.5% 
to 85%), Kassim et al56 (51% to 62%), Stuart D.Blackshell et al57 (45 to 57%) 
and Kulkarni et al81(30 to 40%) in their studies implying that antigen and 
antibody testing should be combined in the early diagnosis of dengue infection.  
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6.6 Significance of testing paired sera 
Significance of collecting paired sera was analyzed by testing 12 samples 
which were negative initially. Three samples which were initially IgM negative 
seroconverted and were IgM positive in the convalescent sample. Four samples 
were positive for IgG which were considered secondary infection cases. 
If paired sera had not been collected and analyzed, these 7 cases would 
have been missed and reported as dengue negative cases. Paired serum analysis 
in this study was found to be statistically significant. WHO insists that testing 
paired sera is mandatory for confirming dengue infections. 
6.7 Primary and secondary infections 
Primary infection is defined by positive IgM and negative IgG, secondary 
infection is by both IgM and IgG positive in the serum samples. With these 
criteria primary and secondary infections could be clearly delineated. 
In the present study 17 (38%) cases were primary infections and 23(52%) 
cases were secondary infections. Kuno et al60 in their study also observed 41% 
and 52% of primary and secondary dengue infections respectively. Neeraja et 
al19 and Ole Wichman et al have however observed more secondary dengue 
cases of 73% & 78% respectively. 
Small children with dengue infections have mostly primary infection and 
are likely to develop only mild symptoms & would not have required 
hospitalization. Being an endemic area the study group had more risk of 
acquiring infection by different serotypes leading to more number of secondary 
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dengue infections. These may be the reasons why more secondary dengue 
infections have been reported in the present study. 
DHF/DSS must be considered a children’s disease because the  paediatric 
age group are innately at increased risk compared with adults.  Due to the high 
mortality in DHF/DSS cases accurate diagnosis is most essential.  
The demographic profile and laboratory investigations of the primary and 
secondary dengue cases were analyzed. The clinical presentation of the children 
with primary dengue infections was less severe in the present study. Age and 
gender between primary and secondary infections was not statistically 
significant. 
Platelet count <105 was noted in 41% of primary infections and 58% of 
secondary infections which was statistically significant. DHF/DSS are more 
common in secondary dengue infections. Testing of platelet count is important 
and planning the management accordingly is vital in dengue cases. 
Although haemorrhagic manifestations like epistaxis, haematemesis and 
malena were noted more in secondary dengue infections (58% vs 47%) it was 
not found to be statistically significant in the present study.  
Haematocrit value in secondary dengue infections (64%) was statistically 
significant in the present study. Balasubramanian et al80 reported that 57.4% 
cases showed haemoconcentration in secondary dengue infections. Neeraja et 
al19 reported 40% in their study.   
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 In the present study USG findings of plasma leakage (77%) amongst 
secondary dengue infections was found to be statistically significant similar to 
the study of Balasubramanian et al80(88.57%). 
6.8 NS1 and its Correlation to Primary and Secondary dengue infections 
The results of NS1 in primary and secondary infection cases were 
analyzed. In the 17 primary dengue infection cases, 59% were NS1 positive, 
whereas amongst the  23 secondary dengue infection cases, NS1 positivity was 
observed only in 22% implying that  NS1 detection is more sensitive in primary 
dengue rather than secondary dengue infections. Duong et al47, Kumarasamy et 
al69, Sekaran et al70 and Koraka et al72 in their studies also observed that NS1 is 
positive in primary than secondary infection. 
Although NS1 antigen is a highly specific and extremely reliable marker 
for the diagnosis of dengue infections, low positivity in secondary infections as 
noted by Kwoon Yong Pok et al46 and Young et al may be due to low viremia, 
immune complex formation and virus serotype. As the present study had more 
secondary infection it would have been reason for the low detection rate in acute 
phase samples. From the present study, it is inferred that serological tests to 
detect dengue viral antigen and antibodies in the serum samples had greatly 
enhanced the ability to effectively & efficiently diagnose dengue infection.  
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7. SUMMARY 
The present study aimed at analysing the role of NS1 antigen detection 
during the acute phase and its correlation in primary and secondary dengue 
infections. 
 65 cases of suspected dengue infections in the age group of 0-12 years 
were included in the study.  
 Majority of the cases were between 5-8 years (43%). 
 More number of male cases were noted (63%). 
 Increased number of cases was seen during the months of November to 
January (70.7%). 
 Fever (100%), vomiting (79%), haemorrhagic manifestations (54%), 
abdominal pain (52%), rashes (6%) and retro orbital pain (3%) were the 
symptoms noted. 
 Haematocrit >35 was noted in 78% of cases. 
 All the patients had a platelet count of <1x105 cells. 48% of the cases had 
count of <5x104 cells. 
 Total leucocyte count of <4000 was observed in 18% of the cases. 
 Pleural effusion was picked up by chest X-ray in 5% cases and by 
ultrasonogram in 25% cases. 
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 NS1 antigen and IgM antibody testing was done to analyse their role in 
the diagnosis of acute dengue infections. Out of the 65 suspected cases, 
46 samples gave a positive result for either NS1 or IgM in the acute phase 
sera, the seropositivity being 70.8%. 
 NS1 was positive in 31% cases and the sensitivity of detection of NS1 
antigen was found to be low, in first 5 days of illness.  
 More NS1 positive cases were seen in day 5 and 7 with five cases on each 
day. 
  63% tested positive for IgM antibody and more number of IgM positive 
cases were seen from day 4 onwards compared to NS1 antigen. 
 NS1 was sensitive in diagnosing 31% of cases and this increased to 71%, 
by a margin of 40% when combined with IgM antibody testing. 
 A paired serum was collected from 45 patients for whom analysis of IgM 
& IgG was done to differentiate primary and secondary dengue 
infections. 
 Three samples which were initially IgM negative, seroconverted and were 
IgM positive in the convalescent sample.4 samples were positive for IgG 
which were considered secondary infection cases. If paired sera had not 
been collected and analyzed, these 7 cases would have been missed and 
reported as dengue negative cases. 
 In the present study 17 cases were primary infections and 23 cases were 
secondary infections. More number of secondary infections were noted. 
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 Platelet count <105 was noted in 41% of primary infections and 58% of 
secondary infections. 
 Haemorrhagic manifestations like epistaxis, haematemesis and malena 
were noted more in secondary dengue infections (58%). 
 Haematocrit value more than 35 was more in secondary dengue infections 
(64%). 
 An USG finding of plasma leakage was 77% amongst secondary dengue 
infections. 
 NS1 was positive in 59% of primary cases and only in 22% of the 
secondary cases. NS1 detection was more sensitive in primary dengue 
rather than secondary dengue infections.The low positivity of NS1 
antigen in the acute samples would have been due to increased number of 
secondary dengue infections seen in the present study.  
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8. CONCLUSION 
 This study highlights the combined use of NS1 antigen and IgM antibody in 
the diagnosis of dengue infection in the acute phase. 
 Testing of paired sera is essential in diagnosis of dengue infection and 
differentiating primary and secondary dengue infection. 
 More NS1 positive cases were seen in days 5 and 7 only. It was low in the 
first five days of illness. 
 IgM was found to be more positive than NS1 in samples collected after the 
fifth day of illness.  
 More number of secondary dengue infections was noted in the study. 
 High NS1 positivity was noted more in primary dengue infection than 
secondary dengue infection.  
 The low positivity of NS1 would have been due to immune complex 
formation as more secondary cases were observed. It would have also been 
due to low viremia or due to the virus serotype which was not confirmed. 
 
 
 
 
S.NO AGE SEX FEVER MYALGIA VOMITI ROP RASH
1 9 M 5 YES YES NO NO
2 12 M 4 NO YES YES NO
3 10 M 4 NO YES NO NO
4 12 F 7 YES YES NO NO
5 10 M 5 NO YES NO NO
6 6 M 6 YES YES NO NO
7 7 F 4 NO NO NO NO
8 8 M 2 NO YES NO NO
9 4 M 7 NO NO NO NO
10 12 F 2 YES YES NO NO
11 6 F 8 YES YES NO NO
12 3 M 5 NO YES NO NO
13 12 M 5 YES NO NO NO
14 6 M 7 NO YES NO YES
15 5 M 7 YES YES NO NO
16 4 M 5 NO NO YES NO
17 2 F 4 NO NO NO NO
18 9 M 7 NO YES NO NO
19 5 M 7 NO YES NO NO
20 2 F 5 NO YES NO NO
46 5 F 3 NO YES NO NO
22 4 F 6 NO YES NO NO
23 8 F 3 NO YES NO NO
24 3 M 7 NO YES NO NO
25 9 F 5 NO YES NO YES
26 8 M 7 NO YES NO NO
27 12 F 5 YES YES NO NO
28 8 M 1 YES YES NO NO
29 8 M 7 YES YES NO NO
30 7 F 2 YES YES NO YES
31 11 F 9 YES NO NO NO
32 3 M 5 NO YES NO NO
33 5 M 5 NO YES NO NO
34 12 M 4 YES NO NO NO
35 7 F 6 NO YES NO NO
36 2 F 5 NO YES NO NO
37 7 F 7 YES YES NO NO
38 6 M 6 YES NO NO NO
39 7 M 7 YES YES NO NO
40 8 M 5 YES YES NO NO
41 10 M 3 YES YES NO NO
42 5 M 5 NO YES NO NO
43 6 F 7 NO YES NO YES
44 3 M 6 YES NO NO NO
45 9 F 4 YES YES NO NO
BLEEDING ABD PAIN HB WBC HCT PLT CXR USG LFT S1
YES YES 12.2 7700 38,3 44000 NORMAL NORMAL N 5
YES YES 13.1 5000 39.9 33000 NORMAL ASCITIS N 4
YES YES 12.5 3400 39 60000 NORMAL PF/AS/GB N 4
NO YES 12 5300 39 98000 NORMAL NORMAL N 7
NO YES 12.8 3800 40.2 1.2 NORMAL NORMAL ELEVATED 5
YES YES 12.2 2900 36.7 84000 NORMAL GB HIGH 7
YES YES 18.1 8200 55.9 28000 NORMAL NORMAL HIGH ENZ 6
NO NO 11.6 13,400 38.1 47000 NORMAL PF N 2
YES NO 10.2 9100 37.5 86000 NORMAL PF,GB, N 7
NO NO 13.1 10,100 41.5 98000 NORMAL NORMAL N 2
NO YES 12.8 6500 36 1.62 NORMAL NORMAL N 6
NO NO 10.3 2,700 34.6 1.4 NORMAL NORMAL N 5
YES NO 13.7 2700 43.2 96000 NORMAL NORMAL N 5
NO YES 8.8 17,700 38 23000 NORMAL HEPA N 7
YES YES 13.2 8200 39.4 68000 NORMAL PF,A N 5
NO YES 11.2 3,800 35 92000 NORMAL HEPA N 5
NO NO 10.7 13,600 34.1 70000 NORMAL NORMAL N 4
NO YES 14.9 5,200 45.5 68000 NORMAL HEPA N 7
NO NO 10 11,000 90000 NORMAL NORMAL N 7
YES NO 12.3 7,000 38.3 49000 NORMAL NORMAL N 5
YES NO 12.2 6,500 39.4 96000 NORMAL BLPF N 3
YES NO 10.7 6,200 35 81000 NORMAL HEPAT N 4
NO YES 11 5,400 34.4 25000 NORMAL NORMAL N 3
NO NO 9.5 12,400 30 58000 NORMAL PF N 7
YES NO 12.2 5,800 38 85000 NORMAL NORMAL N 5
YES YES 15..7 11,800 47.7 18000 PF PF,AS ELEVATED 7
NO NO 13 34,000 39 72000 NORMAL NORMAL N 5
NO NO 12 8,300 37.3 1.2 NORMAL NORMAL N 3
YES NO 9.6 4,600 35.7 71000 NORMAL NORMAL N 7
NO NO 9.5 4,400 37 43000 NORMAL NORMAL N 2
MASTER CHART
YES YES 9.9 4,600 31 2.01 NORMAL LIV,SPLE N 6
NO YES 10.1 5,400 31.8 47000 NORMAL PF ELEVATED 5
YES YES 12.9 18,000 43 55000 NORMAL NORMAL N 5
YES NO 14 8,200 49 44000 NORMAL NORMAL N 6
NO YES 12.2 5,000 39 78000 NORMAL NORMAL N 6
YES YES 10.2 6,200 40.2 68000 NORMAL NORMAL N 5
YES NO 13 5,000 39.9 46000 NORMAL GB HIGH 7
YES NO 11 4,600 38 90000 NORMAL PF N 6
NO NO 13.2 5,100 41.7 88000 NORMAL NORMAL N 6
YES NO 11.3 13,600 33.9 80000 NORMAL NORMAL ELEVATED 5
YES YES 13.1 58,000 39.9 20000 PF PF,GB,LIV N 4
NO NO 14.5 9,300 36 46000 NORMAL PF N 5
YES YES 15 9,200 45.3 29000 NORMAL RF,AS N 7
YES NO 9.7 10,900 33.1 73000 RF RF,AS N 6
NO YES 14.5 4,500 46.2 21000 NORMAL RF N 4
NS1 OD NS UNI  IgM OD IgM UNI IgG OD IgG UNIT S2 IgM OD IgM UNIT IgG OD IgG UNIT
0.07 1.21 0.18 3.76 0.06 2.429 16 1.167 24.36 0.855 34.615
2.35 40.79 2.4 50.104 2.36 95.55 16 2.428 50.69 2.414 97.73
0.07 1.21 2.42 50.52 2.4 97.17 18 0.504 10.52 2.365 95.75
0.669 1.19 0.277 5.78 0.202 8.178 18 0.243 5.07 0.277 11.21
0.065 1.12 1.263 26.37 0.486 19.68 19 0.46 9.6 0.385 15.58
0.137 2.37 0.51 10.65 0.814 32.96 19 2.167 45.24 2.412 97.65
0.048 0.83 2.43 50.73 2.419 97.94 18 2.423 50.58 2.425 98.18
0.057 0.98 2.48 51.77 2.46 99.19 15 2.366 49.39 2.499 101.1
2.528 43.88 2.557 53.38 2.489 100.77 18 2.495 52.09 2.426 98.21
0.056 0.97 2.055 42.9 0.237 9.59 13 0.27 5.64 0.279 11.29
0.115 1.99 0.285 5.94 0.113 4.57 21 0.381 7.95 0.811 32.83
2.446 42.46 2.446 51.06 0.046 1.82 16 2.369 49.46 0.871 35.26
0.042 0.78 0.146 3.05 0.164 6.64 16 0.224 4.68 0.407 16.48
0.061 1.05 0.753 15.72 1.542 62.43 17 1.411 29.46 1.763 71.38
2.173 37.72 2.441 50.96 0.795 32.19 16 2.432 50.77 2.353 95.26
0.056 0.97 2.502 52.23 0.526 21.29 15 2.502 52.23 0.336 13.68
2.554 44.34 2.566 53.57 0.091 3.68 18 2.447 51.08 0.496 20.08
2.405 41.75 2.424 50.6 0.089 3.6 16 2.436 50.86 0.501 20.28
0.113 1.96 0.373 7.79 0.026 1.01 22 0.224 4.68 0.33 1.33
0.141 2.44 2.436 50.86 1.193 48.29 22 1.826 38.16 1.521 61.58
0.16 2.77 0.637 13.29 0.206 8.34 16 1.327 27.7 0.029 1.17
2.485 43.1 2.3 48.01 0.147 5.95 16 2.471 51.59 1.337 54.12
0.058 1 2.134 44.55 2.401 97.2 17 1.135 23.69 2.271 91.94
0.06 1.04 2.498 52.15 2.469 99.54 18 0.34 7.09 0.169 6.84
0.055 0.95 1.011 21.1 0.315 12.75 18 0.386 8.05 0.153 6.19
2.332 40.48 2.346 47.88 1.497 60.61 18 1.426 29.77 2.55 91.29
0.076 1.31 0.209 4.36 0.783 31.7 18 0.31 6.47 0.719 29.1
2.457 42.6 1.293 26.99 0.146 5.91 18 2.54 53.02 0.308 12.47
0.058 0.97 0.371 7.74 0.416 16.84 15 0.232 4.84 0.022 0.89
0.057 0.98 0.267 5.57 0.051 2.06 17 2.441 50.96 2.382 96.44
0.048 0.83 0.332 6.93 0.067 2.71 17 1.849 38.6 0.276 11.17
0.144 2.5 2.482 51.82 2.497 101.9 19 2.4 50.1 2.493 100.93
0.058 1 2.519 52.59 2.606 105.51 18 2.364 49.35 2.344 94.89
0.046 0.79 2.363 49.33 2.364 95.71 18 2.42 50.52 2.415 97.77
0.042 0 0.382 7.97 1.073 43.44 12 0.196 4.05 0.066 2.67
0.078 1.35 0.244 5.09 0.045 1.821 16 0.542 11.31 0.594 24.04
0.085 1.47 2.524 52.69 2.515 101.82 15 2.407 51.21 0.341 13.8
0.362 6.28 2.306 48.14 2.44 98.78 21 2.423 51.55 2.416 97.81
2.433 42.23 2.437 50.88 0.044 1.781 22 2.449 51.13 0.202 8.18
2.337 40.57 1.201 25.07 0.119 4.817 12 2.519 52.59 0.196 7.93
2.556 44.4 2.576 53.78 0.138 5.587 17 0.316 6.59 0.126 5.1
0.04 0.69 2.406 50.23 2.376 96.19 17 2.364 49.35 2.385 96.56
2.307 40.05 2.472 51.6 2.262 91.58 20 2.456 51.27 2.087 84.49
2.408 41.8 2.463 51.42 0.056 2.27 17 2.534 52.9 0.54 21.86
0.035 0.6 2.466 51.48 2.476 100.24 16 2.067 43.15 2.349 95.1
S.NO AGE SEX FEVER
MYALGI
A VOMITI ROP RASH
BLEEDIN
G ABD PAIN HB WBC HCT PLT CXR USG LFT S1 NS1 OD NS UNI  IgM OD IgM UNI IgG OD IgG UNIT S2 IgM OD IgM UNIT IgG OD IgG UNIT
1 10 M 3 NO YES NO NO YES YES 14 14000 36 27,000 NORMAL PF/AS/GB N 4 0.06 1.45 1.638 34.26
2 5 M 3 NO YES NO NO YES LIVER 11 6000 41.9 53000 NORMAL PF/AS/GB N 4 0.2 4.83 1.48 30.96
3 4 M 7 NO YES NO NO NO YES 14.5 6600 46.3 64000 NORMAL NORMAL ELEVATEDN 7 0.09 2.17 1.099 22.99
4 8 M 2 YES YES NO NO NO NO 12 10400 37.7 3.3 NORMAL NORMAL N 3 2.52 54.07 0.105 2.19
5 4 M 5 NO NO NO NO YES NO 11.6 3100 30.7 1.4 NORMAL NORMAL N 5 0.05 1.07 0.087 1.82
6 12 M 4 NO NO NO NO NO NO 13.1 3200 41.3 86000 NORMAL NORMAL ELEVATEDN 4 0.06 1.28 0.688 14.39
7 3 M 4 NO NO NO NO YES NO 7.9 9000 25.3 67000 NORMAL NORMAL N 4 0.113 2.42 1.22 25.52
8 10 M 3 NO NO NO NO YES YES 12.6 10,300 33.4 100000 NORMAL NORMAL N 3 0.11 2.36 0.092 1.92
9 5 M 2 NO YES NO NO YES YES 14.3 15,400 44.2 13000 NORMAL GB ELEVATEDN 3 0.093 1.99 0.077 1.61
10 8 F 2 NO YES NO NO YES YES 16.6 5700 53.8 42000 NORMAL NORMAL N 2 0.216 4.61 0.544 11.38
11 3 F 4 NO YES NO NO NO NO 12 4400 38.6 92000 NORMAL NORMAL N 5 2.469 52.98 0.04 0.83
12 11 M 7 NO YES NO NO YES YES 12.9 6300 40.8 58000 NORMAL HEPATO N 7 0.086 1.82 0.042 0.87
13 7 F 5 YES YES NO NO NO NO 10.9 3000 35 23000 NORMAL NORMAL N 5 1.492 32.01 0.091 1.9
14 10 F 7 NO YES NO NO YES YES 15.2 7800 47.4 20,000 NORMAL NORMAL N 7 2.447 52.51 0.021 0.43
15 8 M 2 YES NO NO NO NO NO 8.6 9800 31.4 1.2 NORMAL NORMAL N 2 0.127 2.72 0.091 1.9
16 3 m 2 NO YES NO NO NO NO 7.8 4,100 26.2 90000 NORMAL NORMAL N 3 2.492 43.26 0.02 0.41
17 6 F 7 YES NO NO NO NO YES 11.5 6,300 36.5 98000 NORMAL NORMAL N 7 0.076 1.35 1.032 21.58
18 10 M 5 YES YES NO NO YES YES 17.4 8,300 49.6 14000 NORMAL NORMAL N 5 0.273 4.73 0.032 0.66
19 10 M 7 YES YES NO NO NO YES 15.9 7,200 49 52000 NORMAL BLPF N 7 0.112 1.94 1.012 21.17
20 11 F 4 YES YES NO NO YES YES 12.1 3,700 39.9 1.1 NORMAL NORMAL N 4 0.061 1.05 0.04 0.83
21 9 M 5 YES YES NO NO YES YES 12.2 7700 38,3 44000 NORMAL NORMAL N 5 0.07 1.21 0.18 3.76 0.06 2.429 16 1.167 24.36 0.855 34.615
22 12 M 4 NO YES YES NO YES YES 13.1 5000 39.9 33000 NORMAL ASCITIS N 4 2.35 40.79 2.4 50.104 2.36 95.55 16 2.428 50.69 2.414 97.73
23 10 M 4 NO YES NO NO YES YES 12.5 3400 39 60000 NORMAL PF/AS/GB N 4 0.07 1.21 2.42 50.52 2.4 97.17 18 0.504 10.52 2.365 95.75
24 12 F 7 YES YES NO NO NO YES 12 5300 39 98000 NORMAL NORMAL N 7 0.669 1.19 0.277 5.78 0.202 8.178 18 0.243 5.07 0.277 11.21
25 10 M 5 NO YES NO NO NO YES 12.8 3800 40.2 1.2 NORMAL NORMAL ELEVATED 5 0.065 1.12 1.263 26.37 0.486 19.68 19 0.46 9.6 0.385 15.58
26 6 M 6 YES YES NO NO YES YES 12.2 2900 36.7 84000 NORMAL GB HIGH 7 0.137 2.37 0.51 10.65 0.814 32.96 19 2.167 45.24 2.412 97.65
27 7 F 4 NO NO NO NO YES YES 18.1 8200 55.9 28000 NORMAL NORMAL HIGH ENZ 6 0.048 0.83 2.43 50.73 2.419 97.94 18 2.423 50.58 2.425 98.18
28 8 M 2 NO YES NO NO NO NO 11.6 13,400 38.1 47000 NORMAL PF N 2 0.057 0.98 2.48 51.77 2.46 99.19 15 2.366 49.39 2.499 101.1
29 4 M 7 NO NO NO NO YES NO 10.2 9100 37.5 86000 NORMAL PF,GB, N 7 2.528 43.88 2.557 53.38 2.489 100.77 18 2.495 52.09 2.426 98.21
30 12 F 2 YES YES NO NO NO NO 13.1 10,100 41.5 98000 NORMAL NORMAL N 2 0.056 0.97 2.055 42.9 0.237 9.59 13 0.27 5.64 0.279 11.29
31 6 F 8 YES YES NO NO NO YES 12.8 6500 36 1.62 NORMAL NORMAL N 6 0.115 1.99 0.285 5.94 0.113 4.57 21 0.381 7.95 0.811 32.83
32 3 M 5 NO YES NO NO NO NO 10.3 2,700 34.6 1.4 NORMAL NORMAL N 5 2.446 42.46 2.446 51.06 0.046 1.82 16 2.369 49.46 0.871 35.26
33 12 M 5 YES NO NO NO YES NO 13.7 2700 43.2 96000 NORMAL NORMAL N 5 0.042 0.78 0.146 3.05 0.164 6.64 16 0.224 4.68 0.407 16.48
34 6 M 7 NO YES NO YES NO YES 8.8 17,700 38 23000 NORMAL HEPA N 7 0.061 1.05 0.753 15.72 1.542 62.43 17 1.411 29.46 1.763 71.38
35 5 M 7 YES YES NO NO YES YES 13.2 8200 39.4 68000 NORMAL PF,A N 5 2.173 37.72 2.441 50.96 0.795 32.19 16 2.432 50.77 2.353 95.26
36 4 M 5 NO NO YES NO NO YES 11.2 3,800 35 92000 NORMAL HEPA N 5 0.056 0.97 2.502 52.23 0.526 21.29 15 2.502 52.23 0.336 13.68
37 2 F 4 NO NO NO NO NO NO 10.7 13,600 34.1 70000 NORMAL NORMAL N 4 2.554 44.34 2.566 53.57 0.091 3.68 18 2.447 51.08 0.496 20.08
38 9 M 7 NO YES NO NO NO YES 14.9 5,200 45.5 68000 NORMAL HEPA N 7 2.405 41.75 2.424 50.6 0.089 3.6 16 2.436 50.86 0.501 20.28
39 5 M 7 NO YES NO NO NO NO 10 11,000 90000 NORMAL NORMAL N 7 0.113 1.96 0.373 7.79 0.026 1.01 22 0.224 4.68 0.33 1.33
40 2 F 5 NO YES NO NO YES NO 12.3 7,000 38.3 49000 NORMAL NORMAL N 5 0.141 2.44 2.436 50.86 1.193 48.29 22 1.826 38.16 1.521 61.58
41 5 F 3 NO YES NO NO YES NO 12.2 6,500 39.4 96000 NORMAL BLPF N 3 0.16 2.77 0.637 13.29 0.206 8.34 16 1.327 27.7 0.029 1.17
42 4 F 6 NO YES NO NO YES NO 10.7 6,200 35 81000 NORMAL HEPAT N 4 2.485 43.1 2.3 48.01 0.147 5.95 16 2.471 51.59 1.337 54.12
43 8 F 3 NO YES NO NO NO YES 11 5,400 34.4 25000 NORMAL NORMAL N 3 0.058 1 2.134 44.55 2.401 97.2 17 1.135 23.69 2.271 91.94
44 3 M 7 NO YES NO NO NO NO 9.5 12,400 30 58000 NORMAL PF N 7 0.06 1.04 2.498 52.15 2.469 99.54 18 0.34 7.09 0.169 6.84
45 9 F 5 NO YES NO YES YES NO 12.2 5,800 38 85000 NORMAL NORMAL N 5 0.055 0.95 1.011 21.1 0.315 12.75 18 0.386 8.05 0.153 6.19
46 8 M 7 NO YES NO NO YES YES 15..7 11,800 47.7 18000 PF PF,AS ELEVATED 7 2.332 40.48 2.346 47.88 1.497 60.61 18 1.426 29.77 2.55 91.29
47 12 F 5 YES YES NO NO NO NO 13 34,000 39 72000 NORMAL NORMAL N 5 0.076 1.31 0.209 4.36 0.783 31.7 18 0.31 6.47 0.719 29.1
48 8 M 1 YES YES NO NO NO NO 12 8,300 37.3 1.2 NORMAL NORMAL N 3 2.457 42.6 1.293 26.99 0.146 5.91 18 2.54 53.02 0.308 12.47
49 8 M 7 YES YES NO NO YES NO 9.6 4,600 35.7 71000 NORMAL NORMAL N 7 0.058 0.97 0.371 7.74 0.416 16.84 15 0.232 4.84 0.022 0.89
50 7 F 2 YES YES NO YES NO NO 9.5 4,400 37 43000 NORMAL NORMAL N 2 0.057 0.98 0.267 5.57 0.051 2.06 17 2.441 50.96 2.382 96.44
51 11 F 9 YES NO NO NO YES YES 9.9 4,600 31 2.01 NORMAL LIV,SPLE N 6 0.048 0.83 0.332 6.93 0.067 2.71 17 1.849 38.6 0.276 11.17
52 3 M 5 NO YES NO NO NO YES 10.1 5,400 31.8 47000 NORMAL PF ELEVATED 5 0.144 2.5 2.482 51.82 2.497 101.9 19 2.4 50.1 2.493 100.93
53 5 M 5 NO YES NO NO YES YES 12.9 18,000 43 55000 NORMAL NORMAL N 5 0.058 1 2.519 52.59 2.606 105.51 18 2.364 49.35 2.344 94.89
54 12 M 4 YES NO NO NO YES NO 14 8,200 49 44000 NORMAL NORMAL N 6 0.046 0.79 2.363 49.33 2.364 95.71 18 2.42 50.52 2.415 97.77
55 7 F 6 NO YES NO NO NO YES 12.2 5,000 39 78000 NORMAL NORMAL N 6 0.042 0 0.382 7.97 1.073 43.44 12 0.196 4.05 0.066 2.67
56 2 F 5 NO YES NO NO YES YES 10.2 6,200 40.2 68000 NORMAL NORMAL N 5 0.078 1.35 0.244 5.09 0.045 1.821 16 0.542 11.31 0.594 24.04
57 7 F 7 YES YES NO NO YES NO 13 5,000 39.9 46000 NORMAL GB HIGH 7 0.085 1.47 2.524 52.69 2.515 101.82 15 2.407 51.21 0.341 13.8
58 6 M 6 YES NO NO NO YES NO 11 4,600 38 90000 NORMAL PF N 6 0.362 6.28 2.306 48.14 2.44 98.78 21 2.423 51.55 2.416 97.81
59 7 M 7 YES YES NO NO NO NO 13.2 5,100 41.7 88000 NORMAL NORMAL N 6 2.433 42.23 2.437 50.88 0.044 1.781 22 2.449 51.13 0.202 8.18
60 8 M 5 YES YES NO NO YES NO 11.3 13,600 33.9 80000 NORMAL NORMAL ELEVATED 5 2.337 40.57 1.201 25.07 0.119 4.817 12 2.519 52.59 0.196 7.93
61 10 M 3 YES YES NO NO YES YES 13.1 58,000 39.9 20000 PF PF,GB,LIV N 4 2.556 44.4 2.576 53.78 0.138 5.587 17 0.316 6.59 0.126 5.1
62 5 M 5 NO YES NO NO NO NO 14.5 9,300 36 46000 NORMAL PF N 5 0.04 0.69 2.406 50.23 2.376 96.19 17 2.364 49.35 2.385 96.56
63 6 F 7 NO YES NO YES YES YES 15 9,200 45.3 29000 NORMAL RF,AS N 7 2.307 40.05 2.472 51.6 2.262 91.58 20 2.456 51.27 2.087 84.49
64 3 M 6 YES NO NO NO YES NO 9.7 10,900 33.1 73000 RF RF,AS N 6 2.408 41.8 2.463 51.42 0.056 2.27 17 2.534 52.9 0.54 21.86
65 9 F 4 YES YES NO NO NO YES 14.5 4,500 46.2 21000 NORMAL RF N 4 0.035 0.6 2.466 51.48 2.476 100.24 16 2.067 43.15 2.349 95.1
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ANNEXURE I- PROFORMA 
DATA SHEET FOR COLLECTION OF SOCIO DEMOGRAPHIC, CLINICAL AND LABORATORY DATA  
FOR  P.G. DISSERTATION WORK ON   
“SERODIAGNOSIS OF DENGUE IN PAEDIATRIC PATIENTS - 
IMPORTANCE OF NS1 ANTIGEN” 
Name  Age   Sex   Hospital 
No. 
 
 
Address  
 
 
Phone 
No. 
 
 
 
 
 
                                                                                                                                                                                                                            
                                                                                                              
 
FEVER  
Duration   
Rigor  
Vomiting  
Retro orbital 
pain 
 
 
Hemorrhagic manifestaions    Respiratory symptoms   
Petechiae   Sore throat  
Echymosis  Rhinitis   
Bleeding gums  Cough   
GIT bleeding  Symptoms of Hepatitis  
Haematuria   Jaundice  
 
Symptoms of CNS involvement   
 
Symptoms of shock  
Altered consciousness  Hypothermia with sweating  
Focal neurological defecit  Restlessness / refusal of feeds  
Fits  Somnolence   
Previous episode  
Family H/O Dengue  
Past H/O hospitalization with platelet transfusion  
BACK PAIN  
MYALGIA  
ARTHRALGIA   
MACULOPAPULAR 
RASH 
 
started on  
spread  
H/O mosquito bite  
Presence of stagnant water around the living area  
 
GENERAL EXAMINATION 
Built  Petechiae  Weight   
Anaemia  Rash   Temperature   
Jaundice  Conjunctival 
congestion 
 Heart rate  
Cyanosis  Pedal edema  RR / SaO2 %  
Lymphadenopathy  Tourniquet 
test 
 BP 
 
 
 
SYSTEMIC EXAMINATION: 
CVS  
RS  
CNS  
Abdomen 
 
 
 
INVESTIGATIONS: 
Hb.  RBS  
TC.   Sr.Protein   
DC.     Urea  
ESR          creatinine  
HCT %  Urine deposits  
PLATELETS  
LFT  
Bld culture  Typhoid  Leptospirosis  
Malaria  chickungunya  JE  
USG  
CXR  
SEROLOGY: 
       Tests             I – sample             II – sample  
       NS1              
       IgM   
       IgG   
 
